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Glioblastoma multiforme is the most aggressive form of human brain tumors due to its 
growth, invasiveness and neurological destructivity. 
The standard WHO-2007 name for 
this brain tumor is “Glioblastoma” 
(GBM); in the tumor grading system 
GBM is considered to be a grade IV
tumor [Table 1]. 
GBM is the most common and most 
aggressive type of primary brain 
tumor, accounting for 52% of all 
primary brain tumor cases and 20% 
of all intracranial tumors. The 
average life expectancy of a patient 
diagnosed with this form of brain 
tumor is on average not more than 
one year (1).
Symptoms of GBM resemble general 
common symptoms for brain tumors 
like headache, seizure, nausea and 
vomiting and hemiparesis but due to 
the location 
Table 1: WHO brain tumor grading system. Human glioblastomais 
considered a grade IV tumor because of its rapid growth, high vascularization
and formation of necrotic tissue surrounded by highly invasive abnormal cells.  
•slow growing cells 
•almost normal appearance under a microscope
•least malignant
•usually associated with long term survival
•relatively slow growing cells
•slightly abnormal appearance under a microscope
•can invade adjacent normal tissue
•can recur as a higher grade tumor
•actively reproducing abnormal cells
•abnormal appearance under a microscope
•infiltrate adjacent normal brain tissue
•tumor tends to recur, often as higher grade
•abnormal cells which reproduce rapidly
•very abnormal appearance under a microscope
•form new blood vessels to maintain rapid growth
•necrotic areas in center 
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of most GBM tumor masses in temporal and frontal lobe,  a progressive   memory-, 
personality-, or neurological deficit is typical. The kind of symptoms produced depends 
highly on the location of the tumor but not necessarily on its pathological properties. The 
severity of symptoms depends mostly on the location and size of the tumor. It is not
uncommon that tumors remain asymptomatic until they reach a certain size. 
A tumor can be visualized using Magnetic Resonance Imaging (MRI). When viewed with 
MRI, glioblastomas often appear as ring-enhancing lesions [Figure1]. Definitive 
diagnosis of a suspected GBM on CT or MRI requires resection of tumor tissue via 
stereotactic biopsy or a craniotomy. Because the tumor grade is based upon the most 
malignant portion of the tumor, biopsy or subtotal tumor resection can result in 
undergrading of the lesion.
Sagittal and coronal contrast-enhanced MRIs of the brain showing the glioblastoma multiforme 
mass. Images by Neuroradiology of the Washington University in St. Louis School of Medicine.
Events or substances that lead to direct GBM development are not yet identified. Most 
glioblastoma tumors appear to be sporadic and without any genetic predisposition. No 
links have been found between glioblastoma and smoking or diet (2, 3). A link between 






                                                                           
has been suggested but recent studies show no evidence for an existing correlation (4, 
5).
Recently, first evidence for a viral association has been discovered. Simian virus 40 
(SV40) and cytomegalovirus  have been found in many tumors of patients leading to the 
conclusion that viral infected tissue causes GBM development (6, 7). There also appears 
to be a link between ionizing radiation and glioblastoma (8). GBM is more common in 
males, although the reason for this is not clear (9).
Other risk factors for GBM include having a lower-grade astrocytoma (brain tumor), 
which occasionally develops into a higher-grade tumor. Occurrence of GBM appears to 
be age related as it increases at ages over 50 years. Furthermore having one of the 
following genetic disorders is associated with an increased incidence of gliomas: 
Neurofibromatosis, Tuberous sclerosis, Von Hippel-Lindau disease, Li-Fraumeni 
syndrome and Turcot syndrome. 
Glioblastoma multiforme is characterized by the presence of small areas of necrotizing
tissue surrounded by anaplastic cells (pseudopalisading necrosis) [Figure 2].
Glioblastoma differs from Grade 3 astrocytomas by 
developing a dense network of hyperblastic blood vessels. 
While oligodendrogliomas form from gray matter, GBM has 
the ability to rise from gray or white matter of the brain. 
However the majority of GBM arises from the deep white 
matter and quickly infiltrates the brain due to a highly 
invasive tumor front. The tumor may extend to the 
meningeal or ventricular wall, leading to a detectable high 
protein content of cerebrospinal fluid (CSF) (> 100 mg/dL), 
as well as an occasional pleocytosis of 10 to 100 cells, 
mostly lymphocytes.  
fixed tissue 
section of human brain 
tumor sections stained with 










                                                                           
Malignant cells can spread to the spinal cord and cause menigeal gliomatosis. However, 
even though the tumor invasion front is very aggressive actual metastaziation is 
extremely rare.  About 50% of GBM occupy more than one lobe of a hemisphere or are 
bilateral. The tumor may take on a variety of appearances, depending on the amount of 
hemorrhage, necrosis, or its age. An MRI or CT scan will usually show a 
nonhomogeneous mass with a hypodense center and a variable ring of enhancement 
surrounded by edema. 
Although clinical research has been very active to find better treatment methods for 
globlastoma multiforme for the last years, the prognosis of glioblastoma remains 
extremely poor.  Several complicating factors cause GBM to be a difficult tumor to treat. 
Foremost, the brain is a sensitive and complex organ susceptible to damage caused by
surgery and chemotherapy. GBM tumor cells on the other hand show a very high 
resistance to chemotherapy and other conventional therapies. The blood brain barrier 
limits treatment possibilities since many drugs are unable to pass it in order to act 
directly on the tumor (10).
The common therapy for patients with glioblastoma multiforme is surgery, radiation 
therapy and the treatment with chemotherapeutic agents that induce DNA damages, 
derogate the DNA-mismatch-repair-system and therefore lead to abortive repair and cell 
death. The most frequently used chemotherapeutics are Carmustin (BCNU) and 
Temozolomide (TMZ).  Alkylating agents are most active in the resting phase of the cell 
therfore these drugs are cell cycle non-specific. Their cytotoxic effect has mainly been 
attributed to alkylation of the O6-position of guanine. Chloroethylation at the O6-position 
of guanine produces an N1-deoxyguanosinyl-N3-deoxycytidyl crosslink. Multiple 
interstrand crosslinks between guanine and cytosine eventually lead to single- and 
double-stranded DNA breaks which in turn are processed by the DNA mismatch repair 
system (MMR). The MMR causes induction of p53 and p21 followed by apoptotic and 




                                                                           
 Alkylating agents like Carmustine (BCNU) or 3-methyl-(triazen-1-yl)imidazole-4-carboxamide
(MITC), the product of the prodrug temozolomide (TMZ), have the ability to attach an alkyl group to the O6 -
position of guanine resulting in O6-alkylgluanine. The induced alkylation can be reversed by the MGMT 
encoded repair enzyme O6- -DNA alkyltransferase ( ) as shown.
Chemotherapeutic treatment with BCNU and TMZ. The chemotherapeutic alkylating agents attack the 
cellular DNA of the cancer cell by guanine alkylation. The resulting formation of O6-alkylguanine (if not 
repaired by the cell) leads eventually to intrastrand cross-links,  and strand 









                                                                           
Meta-Studies have shown that the average life expectance of up to 13% of patients 
diagnosed with GBM can be extended to an average of 2 years if the patients are 
treated with chemotherapeutic agents (14).  However the appearance of recurrent GBM 
tumors in patients occurs often and recurrent GBM tumors tend to be less sensitive to 
chemotherapeutics like Wong et al. showed in another study were they point out that 
only a total of 6% recurrent GBM tumors responded to chemotherapy (15). Multiple 
attributes of human glioblastoma multiforme lead to this observed aggressive and 
invasive growth its high resistance against the common methods of treatment and the 
occurrence of recurrent, highly resistant forms after first treatment (16,17).
Drug resistance may arise through several distinct DNA repair mechanisms that can 
restore the integrity of BCNU and TMZ-induced alkylated DNA bases. Treatment of 
glioblastoma multiforme via surgery is critical but mostly only provides limited benefit due 
to the erratic, aggressive tumor migration with a diffuse progression pattern of the tumor 
invasion front that allows only a fractional removal of the tumor. In more than 90% of 
cases occurs a rise to a recurrent tumor by a residual pool of invasive cells that develops 
immediately adjacent to the resection margin again (18).  In addition there seems to be a 
multitude of resistance mechanisms that can be developed during gliomagenesis and 
the GBM tissue itself seems to become highly heterologous.  
Wilson et al. demonstrated that high levels of a DNA repair enzyme O-6-methylguanine-
DNA methyltransferase (AGT/MGMT) in GBM cells prevent them from critical DNA 
damage induced by chemotherapy (19-21). It was shown in a study by Jaeckle et al. that 
GBM-patients with high MGMT- levels and –activity had an average life expectance of 8 
months while the average life expectance of GBM-patients with low MGMT-activity was 
almost 4 times higher (22). Kokkinakis et al. demonstrated the loss of the p53 inducible 
cell cycle control point as another common mechanism of resistance can be found in 
glioblastoma (23). Further deletions of genes like cyclin-dependent kinase inhibitor 2A
(CDKN2A) or the loss of the allele 10q leads to a weakened impact of chemotherapeutic 
agents on those cells (24-28).
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Recent findings identified the existence of a stem cell-derived origin for gliomas (29). In 
particular, glioma-derived stem-like cells (GSCs) have been isolated from both human 
brain tumors (30) and several glioma cell lines (31). GSCs are crucial for the malignancy 
of gliomas and may represent the consequence of transformation of the normal neural 
stemcell compartment (31, 32).
Treatment of GBM with standard methods appears to lead to selection for GSCs as 
those stem-like cells show strong radiation- and chemotherapy resistance. It has been 
shown that GSCs can be detected and isolated by using the marker CD133. Liu et al. 
demonstrated that CD133 postive cells show higher mRNA levels of genes that inhibit 
apoptosis and are therefore significantly resistant to chemotherapeutic agents like TMZ 
or BCNU  ( .  
Furthermore only small fractions of GSCs are necessary to regenerate the tumor. 
Recurrence of GBM tumors is therefore most likely triggered by resistant GSCs after 
surgery and subsequent therapy as it has been shown that CD133 expression is 
significantly higher in recurrent GBM tissue compared to newly diagnosed tumors ( .  
These alterations in the genome during gliomagenesis together with cellular 
chemotherapy resistance mechanisms lead to a dismal prognosis and significantly 
shortened average life expectancy in GBM patients.  Therefore research for novel 
treatment strategies as a supportive procedure in addition to surgery, radiation therapy 
and chemotherapy that extends the average life expectance of patients diagnosed with 
GBM is necessary.   
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Until the early twentieth century, cancer therapy referred to excision of the tumor by 
surgery. Radiotherapy, chemotherapy, and immunotherapy were shortly to be introduced 
as new treatment strategies. Viruses began to be employed for cancer therapy at the 
end of the nineteenth century. However during this time there was no real concept of the 
nature of a virus yet. Although Beijerinck et al. reported in 1898 that after Chamberland 
candle filtration (through which bacteria could not pass), the agent causing tobacco 
mosaic disease could amplify itself in living, growing plant tissue (35).
In the same year the foot and mouth disease virus, was reported to be the first “filterable 
agent” to be implicated in an animal (36) followed by human yellow fever as the first 
human filterable agent  disease in 1901 (37). However the precise viral identity was still 
unclear until electron microscope imaging of viral particles was possible (38) and the 
advent of cell and tissue culture systems allowed  virus propagation in the late 
1940s, which lead to a better understanding of viral principles (39,40).  culture of 
human cells had become possible in 1948, and attempts to implant these cells into 
laboratory rodents followed, providing the first opportunity to test the  antitumor 
activity of an oncolytic virus under controlled laboratory conditions. 
Moore et al. were the first to investigate oncolytic viruses with a newly developed rodent 
sarcoma cancer model in 1949. Using an  tumor model with the “Russian Far East 
encephalitis virus” they where able to selectively seek out and destroy cancer cells in a 
living animal. In this virotherapy key experiment Moore found that, in certain instances, 
the mouse sarcoma 180 could be completely destroyed, giving first proof of principle for 
the oncolytic potency of an oncolytic virus in a mouse model. However, the virus did also 
show not to be safe for patient admission eventually causing fatal encephalitis in all 
animals (41).
1. INTRODUCTION
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In the years that followed, many other human pathogens were investigated for oncolytic 
activity employing rodent models, including Bunyamwera, dengue, yellow fever, West 
Nile virus, Semliki Forest virus, mumps, vaccinia- and adenovirus (42- 45). Many of 
these were also evaluated in clinical trials showing that complete tumor regression was 
much more likely to occur in the mouse than in the patient. However proof of activity in 
rodent models quickly became a standard experiment to establish proof of principle for 
oncolytic activity of viruses before clinical testing. In early clinical trials Hepatitis viruses 
were among the first to 
be used for therapy. As 
early as 1897 it had 
been noticed that viral 
hepatitis had 
ameliorating effects on 
a variety of human 
diseases. Then in 1949, 
when two patients with 
Hodgkin’s disease were 
observed to go into brief 
remission after 
contracting viral 
hepatitis, clinical trials 
were undertaken (46).
In the early years the Egypt 101 isolate of West Nile virus was used in more than 150 
virus therapy trials against a wide range of cancers [Table 2].
In most trials intra-tumoral virus replication was confirmed in most patients, but tumor 
responses were rare. Immunosuppressed patients with leukemia or lymphoma were 
more likely to respond to therapy, but were also at higher risk of fatal neurotoxicity. Due 
to the lack of efficacy and safety most of these early trials were abandoned while herpes 
viruses, paramyxoviruses, picornaviruses, and adenoviruses emerged as potential 
candidates for gene therapy. Identified as an oncolytic agent in preclinical models in the 
1950s, adenovirus was found to have relatively modest side effects if administered, 
Overview of first significant trials in clinical virotherapy




                                                                           
leading to inflammation but no encephalitis or lethal side effects thus becoming a 
candidate for clinical trials for the treatment of cervical cancer quickly (44). If 
administered into the patient areas of necrosis were present in tumors within 10 days 
and in those who responded to administration, cancerous tissue was shed in large 
amounts. Unfortunately infections were quickly eradicated by the host immune system 
and survival was not significantly prolonged.
It became apparent that even though viruses appeared to have tremendous potential 
adaptation and, ultimately, genetic engineering of viruses was necessary to have a
significant impact on cancer patients. This became a possibility in the early 1990s when 
recombinant DNA technology became a widely used method. At present there is a focus 
on engineering paramyxo-,herpes-, picorna-, pox- and adenoviruses, and most of the
oncolytic viruses currently in clinical testing are attenuated derivatives of prevalent 
human pathogens genetically engineered to further attenuate their pathogenicity, 
increase their oncolytic potency, or enhance their specificity for cancer tissue (47-53).
The aim is to create a specifically tailored virus to infect cancer cells while leaving 
normal cells unharmed. The engineering of such viruses involves ensuring that the 
viruses can only replicate inside cancer cells, lyse s when they exit and ensuring a 
higher dosage at the site of the tumors. This goal can be reached by transductional 
targeting, which means altering the viral surface to ensure that virus binds predominantly 
to cancer cells but not healthy tissue. Another approach is using specific virus activating 
promoters that are known to be highly active in cancer cells like Cox-2 or hTERT to 
ensure transcriptional targeting. However, even with those newfound abilities and 
methods to engineer viral genomes to produce a new generation of safer, specific 
oncolytics, a true therapeutic frontrunner has yet to emerge.
Adenoviral vectors (Ad) are currently the most commonly used viral vector system in the 
field of gene therapy and have successfully been used to transduce a wide variety of cell 
types (54). This is due to several advantages adenoviral vectors have over other viral 
systems. The viral genome is easy to manipulate, they have a large insertion capacity of 
up to 7.5 kb in a non-replicating Ad-System and can be concentrated to titers up to 1010 -
1013 plaque forming units (pfu)/ml. In addition adenoviruses are attractive vectors 
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because they do not integrate into the host chromosome and have a broad tropism,
infect both dividing and non-dividing cells and have a high stability in vivo. Another 
beneficial attribute contributing to their employment in antitumor therapy is that
adenoviruses possess a lytic life cycle that can be exploited for oncolysis.  They are also 
based on pathogenic human viruses and are immunogenic when used .
Adenoviruses were first discovered in 1953 as agents which spontaneously caused 
degeneration of primary cell cultures from human adenoid tissue (55). Since then more 
than 47 human serotypes of the adenoviridae family have been identified and 
adenoviruses have been shown to be responsible for a variety of illnesses including 
upper respiratory disease, epidemic conjunctivitis and infantile gastroenteritis (56).  
Most studies into the structure of adenoviruses have been done with human serotypes 2 
and 5, and have revealed that adenoviruses are icosahedral particles (20 triangular 
surfaces and 12 vertices) 70-100nm in diameter [Figure 4]. 
The virion has a protein shell (capsid) made up of 252 capsomere subunits composed of 
240 hexons and 12 pentons. Each hexon is surrounded by 6 neighboring subunits whilst 
each penton is surrounded by 5 neighboring subunits and has a fiber projecting from its 
vertex. Within the capsid are 4 polypeptides alongside a single copy of the double 
( )  T hree d im ens iona l m ode l o f an  adenovirus  v ir ion v iew ed  a long  an  icosahed ra l th ree- fo ld  
ax is .  ( ) Rep resen ta tive section  o f an adenov irus  v ir ion illus t ra ting  the cu rren t unders tand ing  o f 
po lypep t ide com ponen t and  DNA  in te rac tions. T h is  f igu re  was m od if ied  f rom  Shenk.T (1996 ) 
A denoviridae : T he  v iruses and  their replica tion . ,  97 9-1016. Eds : F ields.B.N, K nipe.D .M &  
Howley .P .M . Lippincott-Raven Pu blishers, P hiladelphia
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stranded DNA genome covalently attached at its 5’ end to the terminal protein 
polypeptide [Figure 5].
The adenoviral genome [Figure 6] is typically around 36 000 bp in length and has 
inverted terminal repeat (ITR) sequences of around 100-140 bp at each end which play 
a role in DNA replication as they contain viral origins of replication. A cis-acting 
packaging sequence is present within several hundred base pairs of the left hand ITR 
and directs interaction of the genome with encapsulating proteins. The genome contains 
5 early transcription units (E1A, E1B, E2, E3 and E4), two delayed early units (IX and 
IVa2) and one major late unit that is processed to generate 5 families of late RNAs (L1-
L5). It has been demonstrated, with the exception of E4 (57), that each early and late 
transcription unit encodes a series of polypeptides with related functions. Two E1A 
proteins are known to activate transcription and induce the cell to enter the S phase of 
the cell cycle (50). Two E1B proteins are known to interact with E1A gene products to 
induce cell growth (50). Three E2 proteins are known to function in DNA replication (56).
E lectron m icroscopy im ages  o f adenovirus  type 5. A  hexon surrounded by six hexons
and  a penton surrounded  by  f ive  hexons are m arked  by dots . Six fibe rs o f tw elve  a re  vis ib le  
p ro ject ing  from  penton capsom eres. F ree pen ton capsom eres contain ing pen ton base and  fibe r
a re  vis ib le.  Magnif ica tion is X  285  000 . Th is  figure  was m odified from  Shenk.T (1996) A denoviridae : The  v iruses 
and  the ir rep lication . Fundam en ta l Virology, 979-1016 . Eds:  Fields .B.N, K nipe.D.M & Howley.P.M. Lipp inco tt -Raven  
P ub lishers , Philade lphia
1. INTRODUCTION




A . B . C .
                                                                           
Schematic representation of the genomes of first generation, second 
generation and gutless adenoviruses (respective map units are indicated). ( ) First generation RAd 
genomes are deleted in E1 and  E3 although the extent of each deletion may vary. Expression cassettes are 
generally inserted into the E1 region but may alternatively be inserted in E3. The extent of E1 and E3 
deletions (relative map units) present within classically used plasmids is indicated. ( ) Second generation 
RAd genomes have additional viral coding regions deleted and these may include E2A (DNA polymerase), 
E2B (precursor terminal protein or DNA binding protein), E3, E4 or IX in various combinations. Expression 
cassettes are generally inserted into the E1 region and the E3 region may be re-introduced. ( ) Gutless 
adenoviral genomes retain only the ITR and packaging sequences from wild type adenovirus. The 
remainder of the genome is comprised of expression cassette(s) and stuffer DNA of varied origin.
E3 proteins play a role in modulation of the anti-viral host response to adenoviruses (58).
Late proteins are either capsid components, or proteins involved in capsid assembly 
(50). The adenovirus life cycle [Figure 7] begins when the adenovirus fiber knob binds to 
a high affinity cell surface receptor (59, 60) called the coxsackie and adenovirus receptor 
(CAR).  For nearly all serotypes either CAR or CD46 (61) serve as the primary HAdV 
receptors on most cell types. The adenovirus then undergoes receptor-mediated 
endocytosis and this is mediated by interactions between an RGD motif within the 
penton base and cell surface avß3 and avß5 integrins (62,63). Once internalised, a drop in 
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pH within the endosome results in a conformational change in capsid structure followed 
by interaction of internal Ad proteins with the endosomal membrane, endosome 
disruption and release into the cytoplasm (64-65) whereupon it becomes localized to the 
nucleus through a process that involves microtubules and dynein (66). To enable this a 
stepwise disassembly of adenovirus particles is necessary which involves fiber release, 
penton base dissociation, DNA capsid scaffold protein degradation or shed, and 
elimination of the capsid stabilizing minor protein (67). When the capsid reaches the 
nuclear membrane the genome enters the nucleus, associates with the nuclear matrix 
through interaction with the terminal protein (68) and the process of early gene 
transcription begins.  
The process of early gene transcription begins with the production of the viral E1A 
transactivator from a constitutive E1 promoter and has 3 main consequences. The first 
consequence is entry of the cell into the S phase of the cell cycle, which is when DNA 
replicates, and this is achieved through a number of ways including inhibition of the 
retinoblastoma tumor suppressor (pRb) by E1A, inhibition of the p53 tumor suppressor 
by E1B-55K and direct inhibition of apoptosis by the Bcl-2 homologue E1B-19K. The 
second consequence is the inhibition of host anti-viral responses and this is done by 
inhibition of a and ß interferon responses by E1A proteins and VA RNAs, retention of 
MHC I molecules in the endoplasmic reticulum by E3-gp19K, inhibition of tumor necrosis 
















down regulation of Fas cell surface expression by the E3 14.5K/10.4K complex, which 
inhibits Fas mediated apoptosis of virus infected cells, and inhibition of FLICE (caspase 
8) which plays a role in TNF and Fas mediated apoptosis (69). The third consequence is 
the synthesis of gene products needed for viral DNA replication.
Once the early gene products are synthesized the processes required for virus 
production are able to begin. DNA replication occurs within the nucleus and after 
transcription of the delayed early IX and IVa2 transcripts the major late promoter 
becomes activated by the IVa2 gene product and promotes production of late RNA 
species. The late RNA species are translated to produce capsid proteins within the 
cytoplasm but capsid assembly does not occur until these proteins are translocated to 
the nucleus. Virus assembly and genome packaging then occurs in the nucleus and 
adenovirus cannot be released from the cell until it is lyzed. This cell lysis requires 
1. INTRODUCTION
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disruption of intermediate filaments (which are components of the cytoskeleton) such as 
vimentin and cytokeratin K18, and results in the collapse of the cell and lysis (70). 
. The adenovirus knob binds to its primary receptor (CAR) (1)  after which 
the penton base interacts with the secondary receptors (avb3/avb5 integrins) (2)  that in turn  trigger the 
process of endocytosis (3) . Once endocytosed acidification of the endosome triggers a conformational 
change in the viral capsid (4)  that is then released into the cytoplasm and translocates to the (5) nucleus. 
The viral genome then enters the nucleus (6) and from its episomal location undergoes transcription (7) and 
then replication (8). Viral gene products are then produced in the cytoplasm following translation (9)  and 
capsid proteins localize to the nucleus where virus assembly occurs (10). Virus can then be released from 
the cell following lysis. Modified from Stone  2000.
1. INTRODUCTION
Figure 7: Adenovirus life cycle
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Although adenoviruses have become a popular choice in current intracranial gene 
therapy they show only inefficient gene delivery into the brain in experimental studies, 
which implies a lower possible clinical efficacy than expected. This leads to the necessity
to develop improved viral gene therapy vectors for a better transduction, intratumoral 
viral spread and transgene expression. Ad5/35.IR.E1A/TRAIL is a recently developed 
adenoviral vector system featuring several modifications that are supposed to overcome 
the observed limitations of viral vectors in intracranial oncolytic therapy. In addition the 
vector promises to show a better biosafety due to its viral replication limitation to cancer 
cells (71, 72) [Figure 8].    
. A modified adenoviral vector for treatment of human glioblastoma 
featuring  improved transduction via capsid modification,  the oncolytic transgene TRAIL and   a 
tumor specific transgene expression. Picture modified from
1. INTRODUCTION
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Ad5/35.IR.E1A/TRAIL combined the adenoviral capsid of serotype 5 (Ad5) with fiber 
proteins of the wild-type serotype 35 (Ad35) (73-75) [Figure 9].  This modification leads 
to a change of the viral receptor from the coxsackievirus and adenovirus receptor (CAR) 
to the human CD46, a membrane-bound regulatory protein that protects tissues from 
complement mediated damage (76-78). This leads to an important alteration in the 
tropism of the vector (79).  CAR expression has been shown to tend to correlate 
inversely with the malignant potential of tumor cells including glioblastoma (61, 80-82) 
which leads to a reduced transduction efficiency of the adenoviral serotype 5 which is 
commonly used in virotherapy. The membrane protein CD46 on the other hand has 
been shown to be expressed in a variety of different cancer cell lines and primary tumor 
cells and its utilization results in a potentially increased transduction efficiency of a broad 
spectrum of different malignant tumor cells (83+84).
: Adenoviral serotype 5 and 35 with their corresponding cellular receptors. The chimeric Ad5/35 
virus features a serotype 5 capsid with the shorter fiber knob of  serotype 35.   
1. INTRODUCTION






                                                                           
In 1995, TNF related apoptosis-inducing ligand (TRAIL), also known as Apo-2L (85), 
was first identified based on its sequence homology to other members of the TNF 
superfamily (86). TRAIL is a type II transmembrane protein and shows highest homology 
to CD95L, exhibiting 28% amino acid identity with amino acid  identity in the extracellular 
receptor-binding motif. TRAIL triggers apoptosis upon engagement of one of its two 
agonistic receptors, DR4 (death receptor 4) (87) and DR5 (death receptor 5), both type-I 
transmembrane proteins homologous to other members of the TNFR family (88+89).  
On the other hand two main antagonistic receptors exist, namely TRID or TRAIL-R3 and 
TRUNDD or TRAIL-R4 (84, 85, also described as DcR1 (decoy receptor 1) and DcR2 
(decoy receptor 2), respectively. DcR1 contains an incomplete homophilic death domain 
(DD) and is unable to transduce a death signal. Similarly, DcR2 lacks a cytoplasmic 
domain and is bound to the cell surface via a glycosyl-phosphatidylinositol (GPI) anchor
and does not mediate apoptosis upon ligation. Transient overexpression of DcR1 or 
DcR2 in TRAIL-sensitive tumor cells prevents cell death triggering by TRAIL (90+91), 
and recent evidence indicates that tumor and normal cells can acquire resistance to 
TRAIL-induced killing by up-regulating TRAIL antagonistic receptors (92-95).  
In case of TRAIL binding to DR4 and DR5 ligand-induced crosslinking initiates 
recruitment of various adaptor molecules through DD interactions. This includes Fas-
associated death domain (FADD), which directly binds procaspase-8 to the ligated 
receptor to form the death-inducing signaling complex (DISC). This, in turn, promotes 
trans-catalytic activation of procaspase-8 and -10 which are activated by autoproteolytic 
cleavage and initiate the caspase cascade leading to apoptosis (96) [Figure 10 ].
TRAIL expression can selectively induce apoptosis in tumorigenic or transformed cells, 
but not in normal cells, highlighting its potential as therapeutic application in cancer 
treatment. Therefore TRAIL has gained considerable interest in oncology since it 
displays specific antitumoral activity against a wide range of tumor cells including 
glioblastoma (97-100). Furthermore first experiments in rodents and primates have not 
shown any significant side effects (101+102).
1. INTRODUCTION
1.3.2  The transgene: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand   
(TRAIL)
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 TRAIL 
binds to DR4 or DR5 receptors. The resulting cross-linking recruits Fas-associated death domain (FADD) 
which in turn binds pro-caspase-8. The resulting complex is described as the “death-inducing signaling 
complex” (DISC). Activation of Pro-caspase-8 by the DISC initiates the caspase-cascade which induces 
apoptosis. 
To minimize cytotoxicity and avoid viral spread into non cancerous tissue, nonreplicating 
adenoviral vectors have been commonly used in the past (103+104). In these vectors 
the E1A region of the viral genome has been deleted (AdE1-) which renders the virus 
unable to synthesize the gene products necessary for viral DNA replication.
Recently a new concept for tumor-specific gene expression that is based on homologous 
recombination between inverted repeats (IR) in adenovirus genomes has been 
developed (Ad.IR) (105).  The IRs inserted into the E1 region of AdE1– vectors mediate 
predictable genomic rearrangements depending on viral DNA replication. This system 
1. INTRODUCTION
Figure 10: TNF related apoptosis-inducing ligand (TRAIL) mediated induction of apoptosis.
1.3.3 Tumor specific viral replication and transgene expression
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uses adenoviral vectors deleted for all E1A and E1B genes which are capable of low 
level replication of their viral DNA despite the deletions in tumor cells but not in non-
dividing cells. 
In case of Ad5/35.IR-E1A/TRAIL inverse homologous elements flank an RSV promoter 
with a bicistronic expression cassette located downstream of the adenovirus packaging 
signal (? ) and the viral inverted terminal repeats (AdITR).  Since the promoter is located 
upstream of the bicistronic expression cassette in inactive 3’-5’ orientation, transgene 
expression is not possible. However in case of viral replication, homologous 
recombination can occur and the elements mediate the formation of genomic derivatives 
containing the promoter in a transcriptionally active position [Figure 11]. This leads to 
transcription of the transgenes TRAIL and E1A. Expression of E1A allows for efficient, 
tumor-specific viral replication and production of progeny virus, whereas expression of 
TRAIL upon viral replication and TRAIL-mediated apoptosis confers efficient release of 
progeny virus and viral spread. 
  
Homologous recombination through elements that flank a 
bicistronic expression cassette allows to transcriptional activation which leads to E1A expression which is 
the essential product for tumor-specific viral replication.
E1A  TRAIL
1. INTRODUCTION
Figure 11: Tumor specific viral replication.
TRAIL + E1A
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In this study we wished to determine whether a novel virotherapeutic approach with a 
modified adenoviral vector utilizing a chimeric capsid consisting of a serotype 5 capsid 
and serotype 35 fiber is generally applicable in case of human glioblastoma. We propose 
an enhanced transduction ability of the chimeric capsid as compared to commonly used 
Ad serotype 5. Furthermore we want to evaluate if the tumor specific  expression of the 
transgene TRAIL allows for improved infection and cell killing of human GBM cells 
compared to wild-type serotypes 5, 35 and an adenoviral Ad5/35 construct that does not 
express TRAIL.  In addition, we want to verify the oncolytic potential of 
Ad5/35.IR.E1A/TRAIL in GBM tumor tissue after intratumoral injections into 
subcutaneously xenografted glioblastoma tumors in NOD/SCID mice.  We suggest that 
an oncolytic adenoviral vector that allows efficient infection of glioblastoma cells, 
replicates specifically in infected tumor tissue and expresses ligands that induce 
apoptosis in the tumor shortly after infection or block the tumor invasion activity of 
glioblastoma could provide a promising therapeutic option.
in vivo
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1.5 ml Tubes Fisher Scientific, Hampton, NH, USA
96-well plates Fisher Scientific, Hampton, NH, USA
Cell Strainer (70 µm) BD Biosciences, San Jose, CA, USA
Centrifuge Tubes Corning, Corning, NY, USA
Conical Tubes BD Biosciences, San Jose, CA, USA
Dishes, TC-treated Corning, Corning, NY, USA
Electroporation Cuvettes, 1mm BTX, Holliston, MA, USA
FACS tubes BD Biosciences, San Jose, CA, USA
Filter units (0.22 µm) Millipore, Billerica, MA, USA
Glass-pipettes Bellco, Vineland, NJ, USA
Gloves Kimberly Clarke, Roswell, GA, USA
Pasteur Pipettes Fisher Scientific, Hampton, NH, USA
PCR tubes CLP, San Diego, CA, USA
Petri Dishes (non TC-treated) Fisher Scientific, Hampton, NH, USA
Pipette Tips Island Scientific, Bainbridge, WA, USA
Plastic-pipettes Fisher Scientific, Hampton, NH, USA
Polypropylene tubes BD Biosciences, San Jose, CA, USA
TC flasks BD Biosciences, San Jose, CA, USA
ABI 3730 DNA Analyzer ABI, Foster City, CA, USA
Binocular  (Optix) Olympus, Japan
Centrifuges 
   (5415D Tabletop)
   (5415C Tabletop)
   (RC3B Plus, Sorvall)
   (GS-6R)
Eppendorf, Hamburg, Germany
Eppendorf, Hamburg, Germany
Fisher Scientific, Hampton, NH, USA
Beckman, Fullerton, CA, USA
Electroporation (Gene Pulser Xcell) BioRad, Hercules, CA, USA
FACSCalibur BD Biosciences, Rockville, MD, USA
FACSVantageSE BD Biosciences, Rockville, MD, USA
Fluorometer (DyNA Quant 200) Hoefer, San Francisco, CA, USA
Gel Electrophoresis Chamber
   (SEA 2000)
Ellard Instrumentation, Monroe, WA, 
USA
Elchrom Scientific, Cham, Switzerland
:  General consumables
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Gel Illuminator (Universal Hood II) BioRad, Hercules, CA, USA
Heatblock (Dry bath incubator) Fisher Scientific, Hampton, NH, USA
Hemocytometer Hausser Scientific, Horsham, PA, USA
Hotplate (PC-351) Corning, Corning, NY, USA
Incubators 
   (Forma Scientific) 
   (Isotemp)
   (ShelLab)
Fisher Scientific, Hampton, NH, USA
Fisher Scientific, Hampton, NH, USA
ShelLab, Cornelius, OR, USA
Liquid Nitrogen Tank (Locator 4plus) Barnstead/Thermolyne, Dubuque. IO, 
USA
Microscope (CK40) Olympus, Japan
Microwave (Carousel 1200 Watts) Sharp, Mahwah, NJ, USA
PCR Thermocycler 
   (GeneAmp PCRSystem 9700) 
   (2720 ThermalCycler)
   (DNA Engine DYAD)
ABI, Foster City, CA, USA
ABI, Foster City, CA, USA
MJ Research (BioRad)
PH-Meter Beckman, Fullerton, CA, USA
Pipet-Aid Drummond Scientific, Broomall, PA, USA
Pipettors 
   (Pipetman P) 
   (Eppendorf Research)
Gilson, Middleton, WI, USA
Eppendorf, Hamburg, Germany
Power Supply 
   (EC-135)
   (EC-105)
   (Model 200/2.0)
ECApparatus Corp., Holbrook, NY, USA
ECApparatus Corp., Holbrook, NY, USA
BioRad, Hercules, CA, USA
Scale (Accu-413) Fisher Scientific, Hampton, NH, USA
Shaker 
   (Orbit Shaker)
   (MaxQ 3000)
Barnstead/Lab-line, Dubuque, IO, USA
Barnstead/Lab-line, Dubuque, IO, USA
TaqMan Machine 
   (7500 Real Time PCR System) ABI, Foster City, CA, USA
Thermomixer Eppendorf, Hamburg, Germany
Vortex 
   (Mini)
   (Type 16700)
Fisher Scientific, Hampton, NH, USA
Barnstead/Thermolyne, Dubuque, IO, 
USA
Waterbath 
   (Sheldon)
   (Aquabath)
ShelLab, Cornelius, OR, USA
Barnstead/Lab-line, Dubuque, IO, USA
:  General lab equipment





The following antibodies were used for immunofluorescence experiments and flow 
cytometry (Table). Listed are the antibody target, the host where the antibody was raised 
in, the dilution factor used in the experiments, and the vendor where the antibody was 
purchased from using the appropriate catalog number. If not stated otherwise, antibodies 
were directed against human antigens.
:  primary- & secondary antibodies used for immunofluorescence experiments in this study.  
FITC=fluorescein isothiocyanate
The following adenoviruses were used in this study. Listed are viruses, the transgenes 
they carry, the promoters used for expression of transgenes, and their origin.








CAR mouse 1:50 Abcam Ab 9891-1
CD 46 mouse 1:50 BD Biosciences clone J4.48
Hexon (adenovirus) goat 1:100 Chemicon MAB8052
MHC class I mouse 1:50 BD Biosciences clone G46-2.6
IgG- mouse 1:50 BD Biosciences 555749
 goat IgG/Texas 
Red
rabbit 1:200 Abcam Ab 6739-1
-mouse IgG/FTIC rat 1:200 BD Biosciences 550003





E1A, TRAIL RSV Sova et al., 2004
Ad5.IR-
E1A/TRAIL
E1A, TRAIL RSV Sova et al., 2004
Ad5/35-GFP GFP RSV Shayakhmetov et al., 2000
α
α
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3.1.6. Mouse strain 
3.1.7 Cultured cells and culture media
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Ad5/11-GFP GFP RSV Shayakhmetov et al., 2000
Ad5/11-GFP GFP RSV Shayakhmetov et al., 2000
Ad35 - - Holden strain (ATCC)
Ad5 - - Reference strain (ATCC)
Ad5 hexon Forward 5' TACTGCGTACTCGTACAAGG 3'
Ad5 hexon Reverse 5' AGAGCAGTAGCAGCTTCATC 3'
HPRT1 Forward 5' AGTTCTGTGGCCATCTGCTT 3'
HPRT1 Reverse 5' GCCCAAAGGGAACTGATAGTC 3'
Table 6: Adenoviruses used in this study. TRAIL=tumor necrosis factor-related apoptosis-inducing ligand, 
GFP=green fluorescent protein, RSV=rous sarcoma virus,
All oligonucleotides were purchased as lyophilized, salt-free stocks from Operon. The 
following tables list oligonucleotides used for the detection of adenoviral l genomes by 
qRT-PCR. The official gene symbol (by Human Genome Organization (HUGO) Gene 
Nomenclature Committee) was used for oligonucleotide (primer) names.
Table 7: Oligonucleotides used in this study
All animal experiments in this study have been performed with the strain “NOD.CB17-
Prkdcscid/NCrCrl” (NOD/SCID). In this strain the SCID mutation has been transferred 
onto a non-obese diabetic background. Animals homozygous for the SCID mutation 
have impaired T and B cell lymphocyte development. The breeding pairs were obtained 
through Charles River Laboratories Wilmington, MA, USA). 
The listed cells and culture media were used throughout this thesis. For cell passaging, 
cells were detached from tissue culture plates (BD Falcon) with trypsin solution (Gibco) 
and then washed with PBS (Gibco). To determine cell numbers, cultures were counted 
Primer Direction Sequence
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Table 8
3.2 Methods
3.2.1 Surface protein immunofluorescence analysis using flow cytometry
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using a hemocytometer. 1% Penicillin/Streptomycin (Gibco) was added to all media. 
Cells were propagated in a 1:3 ratio and cultured in DMEM containing 10% FBS, Non-
Essential Amino Acids Solution, and L-glutamine (Gibco). All cells were cultured at 37 C, 
5% CO2, and 95% humidity in cell culture incubators. Cells were frozen in cryo tubes 
(Greiner) in 50% FBS, 40% of indicated medium and 10% dimethyl sulfoxide using a cell 
freezer with isopropanol 
: Cells and their cell culture media. FBS=fetal bovine serum
Immunofluorescence analysis of CAR and CD46 expression was performed by flow 
cytometric analysis. U-87 MG, T98G, and SF767 cells were trypsinized and pelleted via 
centrifugation. Cell pellets were resuspended in ice-cold PBS with 1% FBS in order to 
block unspecific antibody binding. 2x105 cells were incubated with with a mouse -








(Graham et al., 1977)
human embryo kidney cells, 
transformed by adenovirus 
serotype 5 E1A
DMEM (Gibco), 




(Bruder et al., 2000)
human lung adenocarcinoma 
epithelial cells, adenoviral E1-
complementing cell line 
derived from A549 cells
DMEM (Gibco),




(Stein et a. 1979) 
human glioblastoma cell line 





Non-Essential Amino Acids 
Solution (Gibco)
SF767
Brain Tumor Research 
Center (University of 
California San Francisco, 
CA) (Berens et al., 1990)








(Beckman et al. 1971)
human glioblastoma cells, 





Non-Essential Amino Acids 
Solution (Gibco)
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human Coxsackie Adenovirus Receptor (hCAR) primary antibody (Abcam Inc., 
Cambridge, MA , USA)  in 5ml round bottom tubes (BD Falcon) in a total of 100 l for 45 
min on ice. All subsequent incubation steps were carried out in the dark. Cells were 
washed with 3 ml PBS+1%FBS and centrifuged at 400xg for 5 min at 4 C in between.  
This was followed by a 45 minute incubation with a secondary FITC labeled -mouse 
IgG antibody (BD Biosciences; San Jose CA USA). One well containing cells of the 
same cell line was harvested but only incubated with the secondary antibody as a 
negative control. After incubation the cells were washed, fixed with 4% 
paraformaldehyde and analyzed via flow cytometry. The BD FACSCanto™ flow 
cytometer (Becton Dickenson) running the FACSDiVa software was used to analyze 
samples. Unspecific background of individual channels was determined using 
fluorophor-labeled isotype controls and color compensation was achieved with single 
color-stained samples. Figures were generated using CellQuest for Macintosh (Becton 
Dickinson). 
Adenoviruses were propagated on HEK-293 cells in 150 mm dishes in a total volume of 
20ml. For propagation of Ad5/35.IR-E1A/TRAIL and Ad5.IR-E1A/TRAIL the more 
apoptosis-resistant AE25 cell line was used. Cells were 90-100% confluent when 
infected. For initial infection, replication competent adenovirus (RCA)-free aliquots of 
virus-stocks were used in an approximate MOI of 10-25 pfu/cell. 5ml fresh medium was 
added the next day. When cells were rounded and started to de-attach (approximately 
48 hours after infection), they were harvested in the culture medium by repeated 
pipetting. Cell-containing medium was transferred to a 50ml blue cap tubes (BD Falcon) 
and these then subjected to 4 cycles of freezing in liquid nitrogen and thawing at 37 C in 
a water bath. Tubes were centrifuged at 400xg (Beckman Coulter) and the supernatant 
was collected. Virus-containing supernatant was propagated on fresh HEK-293 or AE25 
cells in a ratio of 1:3-1:4 until 30 150mm dishes were infected. Here, cells were collected 
when rounded, but before they started to detach (approximately 36 hours after infection). 
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saline (PBS [Gibco BRL]) per plate. After 4 cycles of freezing and thawing, virus was 
isolated by ultracentrifugation. The first ultracentrifugation (2 hours, 14 C, 35,000 RPM, 
SW41 rotor [Beckman Coulter]) was performed in a Caesium chloride (CsCl) step 
gradient. The following CsCl concentrations were layered above each other in 12ml 
ultra-clear tubes (Beckman Coulter): 
i)    0.5 ml 1.50 g/cm3 CsCl (45.41g CsCl + 54.49 ml H2O)
ii)   3.0 ml 1.35 g/cm3 CsCl (35.18g CsCl + 64.82 ml H2O)
iii)  3.5 ml 1.25 g/cm3 CsCl (26.99g CsCl + 73.01 ml H2O).
5ml of viral supernatant were layered on top of the gradient and then tubes were 
centrifuged in a SW41 rotor for 2  hours at 35,000 RPM at 14 C (Beckman Coulter). 
Three clearly separated bands were obtained. Adenovirus appeared as a narrow, 
opaque white band in the lower 1/3 of the CsCl step gradient (Fig.12). 
Fig 12: Cesium 
chloride separation of adenovirus from defective particles and cell debris.
Adenovirus fractions of individual tubes were isolated and combined. 4ml were mixed 
with 8 ml 1.35 g/cm3 CsCl in ultra-clear tubes and then centrifuged at 35,000 rpm 
overnight. The virus band was isolated from the bottom 1/4 of the tube and then dialyzed 
in a 50kDa cut-off dialyzing tube (Spectrum Laboratories) against 1,000 ml of 10 mM 
Tris pH 7.5, 10mM MgCl2, 250mM NaCl and 10% glycerol overnight at 4 C with one 
change of dialyzing buffer. The virus was then collected and stored in 25 l or 50 l 
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3.2.3 Adenovirus titering by spectrophotometry
3.2.4 Adenovirus titering by plaque assay
3.2.5 Crystal violet cytotoxicity assay
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The adenovirus particle titer was determined on viral DNA. A 25 l aliquot from a fresh 
adenovirus stock was added to 475 l TE buffer (10mM Tris pH 8.0, 1mM EDTA pH 8.0 
[Sigma]) with 0.1% SDS (Sigma). The sample was thoroughly mixed using a vortexer 
(Baxter) for 5 min and then centrifuged at 14,000 RPM using an Eppendorf table 
centrifuge for 5 min. The optical density (OD) of supernatant was assessed at 260 nm in 
a spectrophotometer (Becton Dickenson). Viral particle titer/ml was calculated by 
multiplying the OD with 2x1013 as described by Mittereder at al. 1996. 
HEK-293 cells were used to determine the plaque-forming unit titer of adenovirus stocks. 
Cells were plated in 6-well plates and infected when 90-100% confluent. An aliquot of 
the adenovirus stock was thawed on ice and then serial diluted in regular HEK-293 
medium using the following dilutions: 10-2, 10-4, 10-6, 10-8, 10-9, 10-10. Cells were 
then infected in duplicates with 1ml virus dilution/well and incubated for 24 hours at 
37 C. Medium was removed and cells then overlayed with 3ml of a warm (45 C) mix of 
2xDMEM (Gibco) and 1.2% agarose (Sigma) (1:1 vol/vol) supplemented with 10% FBS. 
Cells were overlaid with 1 additional ml on days 4 and 9 after the first overlay. Plaques 
were counted on days 10 and 14 post infection and final titer was determined by 
multiplication of individual plaques with appropriate dilutions. The mean titer of 
duplicates was used.
Cells were plated in 24-well dishes and kept in culture until they were nearly confluent. 
After estimation of the total number of cells per well via “Helber” counting chamber, the 
cells were infected with an MOI of 1 or 10. Over a period of 6 days one well per viral 
serotype 5 and 35, Ad5/35.IR.E1A/GFP and Ad5/35.IR.E1A/TRAIL was stained every 24 
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3.2.6 MTT assay
3.2.7 In situ apoptosis detection using the TUNEL assay
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for 10 min in 4% paraformaldehyde at room temperature. Fixed cells were washed with 
PBS and incubated for 5 min in 1% crystal violet solved in 70% ethanol (Sigma), 
followed by three rinses with water. Air-dried cells were photographed.
An MTT stock solution of 5mg/ml (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (Sigma) was constituted in PBS (Gibco) and stored at -20 C. MTT assays were 
carried out in 96 well plates (Fisher). At 4 or 8 days post infection 20µl of MTT stock 
solution (in PBS) was added to each well and cells were incubated for 2h at 37°C. 
Medium was removed, cells washed twice with PBS and air-dried. Then 100µl of 
DMSO/well was added per well and incubated for 30min at RT in order to dissolve 
crystals. Absorbance was measured in plate reader (EL 340, Bio-Tek Instruments) at 
546nm. 
The TUNEL (terminal dUTP nick-end labeling) assay can be used to detect apoptotic 
cells. Cells of the two human GBM lines U-87 MG and SF767 were grown in 24-well cell 
culture dishes. After the mono-cell layer was nearly confluent, the average number of 
cells per well was estimated using a “Helber” counting chamber (improved Neubauer, 
Fisher Scientific). Cells were infected with adenovirus serotype 35 wild-type,  Ad5/35.IR-
E1A/TRAIL or the vector Ad5.IR-E1A/TRAIL with an MOI of 1 pfu/cell.
Wells of each cell line were harvested 48 and 96 hours post- infection. Induced 
apoptosis was detected via visualization of occurred DNA fragmentation by labeling of 
free 3’- OH termini with FITC with an in situ cell death detection kit (Roche, Palo Alto, 
CA, USA). The cells were collected after trypsin treatment, fixed with 4% 
paraformaldehyde and processed following the protocol of the kit manufacturer. The 
labeled cells were analyzed using flow cytometry. The BD FACSCanto™ flow cytometer 
(Becton Dickenson) running the FACSDiVa software was used to analyze samples. 
Unspecific background of individual channels was determined using fluorophor-labeled 
°
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3.2.8. qPCR for viral genomes
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isotype controls and color compensation was achieved with single color-stained 
samples. Figures were generated using CellQuest for Macintosh (Becton Dickinson). 
Confluent cells of the U-87 MG and T98G cell lines were transduced with an MOI of 100 
using Ad5/35.IR-E1A/TRAIL or Ad5/35.IR-E1A/GFP. The experiment was stopped 3 
hours or 3 days post infection. Cells were washed with PBS, trypsinized, washed with 
RPMI+10% FBS and washed again with PBS twice. Nucleic acids from cell pellets were 
isolated using the AllPrep DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s 
protocol. 1ng DNA per reaction was used for further analysis. A standard curve for 
genomic DNA (isolated from SKOV3-ip1 cells) was prepared based on the equation that 
one copy number equals 3pg of genomic human DNA (6pg/diploid cell). Primers against 
Ad5 hexon were used to assess the viral copy number in viral genome preparations from 
fixed numbers of viral particles (assessed spectrophotometrically), serially diluted and 
spiked with 1 ng genomic DNA of SKOV3-ip1 cells to generate a standard curve. All 
reactions were performed in triplicate in a total reaction volume of 15µl using ImmoMix 
(Bioline), SYBR green (Bioline) and 3 µmol/l of each primer, and carried out in the 
GeneAmp 7900 instrument (Applied Biosystems). The following parameters were used 
for amplification and melting curve analysis: 95°C (10 minutes), followed by 40 cycles of 
60°C (2 minutes), 95°C (15 seconds), 60°C (15 seconds), 95°C (15 seconds). Ct values 
were calculated using the Sequence Detection System software (Applied Biosystems). 
Under these conditions at least 10 copies could be detected for each replicate. Levels of 
hexon were standardized per DNA genomic copy number using primers against 
housekeeping gene HPRT1. All primer sequences are supplied in Table 7.
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3.2.9. Detection of apoptotic/necrotic tissue and viral capsid protein in 
xenografted tumor tissue after viral treatment 
3.2.10. Immunohistochemistry on tumor sections 
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U-87 cells were harvested and 2 x 106 cells were resuspended in 200 µl PBS.
The cells were mixed with 200 l Matrigel  (BD Biosciences; San Jose CA USA) and 
injected subcutaneously into both flanks of NOD/SCID mice. Pre-established s.c. tumors 
were treated with injections of 1 x 108 pfus of the onclolytic adenovirus Ad5/35.IR-
E1A/TRAIL or the adenoviral serotype 35 directly into the xenografted tumor. Mice were 
sacrificed 2 weeks after viral application and tumor tissue samples were embedded in 
OCT (Tissue-Tek)  and frozen. Tumor tissue was sliced (0.8 microns) using the Leica 
CM 1850 cryostat (Leica Microsystems) and then transferred onto superfrost slides 
(Fisher Scientific). Slides were fixed in acetone (Fisher Scientific) for 10 min at -20oC. 
After two rinses with PBS (Sigma) slides were blocked with 2% milk powder (BioRad) in 
PBS for 20 min at room temperature. Microdissections were processed and analyzed for 
apoptotic/necrotic tissue using the “in situ cell death detection assay” (Roche) following 
the protocol of the kit manufacturer. Adenoviral hexon capsid proteins were detected 
using a goat  Ad-hexon capsid protein antibody (Chemicon AB 1056, Temecula, CA 
USA) and a secondary Rabbit  goat IgG H&L (Texas Red) antibody (Abcam Inc. 
Cambridge, MA USA).
Tumor sections of animal xenografts were snap frozen embedded in OCT compound 
(Tissue-Tek) on dry ice. OCT embedded tissues were then stored at -80oC and 
equilibrated to -20oC for at least 1 hour prior to sectioning. Tumor tissue was sliced (0.8 
microns) using the Leica CM 1850 cryostat (Leica Microsystems) and then transferred 
onto superfrost slides (Fisher Scientific). Slides were fixed in acetone (Fisher Scientific) 
for 10 min at -20oC. After two rinses with PBS (Sigma) slides were blocked with 2% milk 
powder (BioRad) in PBS for 20 min at room temperature.  Microdissections were 
processed and analyzed for surface proteins using the  “K1390 Envision system” (Dako) 
following the manufacturer’s protocol.  CD46 was detected with the a- CD46 (mouse a-
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3.2.11 Animals and treatment protocol
33
conjugated goat a- mouse antibody. Parallel to this sections were incubated with either a  
mouse a- human MHCI antibody as a positive control or an Igg negative control 
antibody. After application of the substrate-chromogen cells were counterstained using 
Gill's hematoxylin counterstain. 
U-87 cells were harvested and 1x106 cells were resuspended in 100 l PBS. The cells 
were mixed with 100 l Matrigel  (BD Biosciences; San Jose CA USA) and injected 
subcutaneously into the flanks of Four- to 6-week-old male athymic NOD/SCID mice 
using a 271/2 G syringe (Becton Dickinson, NJ, U.S.A.). 
For each wild-type virus serotype, viral vector and one negative control (NeCo) 5 mice 
received injections into both flanks. Tumor growth was measured every other day using 
a caliper. Once the tumors reached an average size of 55 mm3 ±15%, viral treatment 
was initiated: 1 x 108 pfu of Ad5, Ad35, Ad5/35.IR-E1A/GFP or Ad5/35.IR-E1A/TRAIL 
were injected intratumorally. The same dose was given 48 hours after the first injection 
leading to a total application of 2 x 108 pfu. Further increase or reduction of the tumor 
volume was measured using a caliper. In a second approach 1 x 104 U-87 MG cells 
were transduced with the wild-type serotype Ad5, Ad35 or the vector Ad5/35.IR-
E1A/TRAIL using an MOI of 100. 12 h.p.i. the cells were harvested and resuspended 
together with 9.9 x 105 uninfected U-87 MG in 100 l PBS. The cells were mixed with 
100 l Matrigel  and injected subcutaneously into the flanks leading to an injection of 
1 x 106 U-87 MG cells with 1% transduced cells. For each wild-type virus serotype, viral 
vector and one negative control containing no previously infected cells 5 mice received 
injections into both flanks tumor growth was monitored every 48 hours using a caliper. 
Differences amongst groups of tumors were compared statistically using the Mann 
Whitney U Test. All experiments were conducted under protocols approved by the 
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4. Results
4.1 Human GBM cell lines show higher expression of CD46 compared
to CAR
35
A limitation of cancer therapy with adenovirus vectors has been the lack of CAR 
expression on tumor cells since CAR is the primary receptor of the adenoviral serotype 5 
which has been used extensively in adenoviral gene therapy in the past.  
For comparison of the impact of the oncolytic vector Ad5/35.IR-E1A/TRAIL on human 
glioblastoma cell lines, adenovirus serotype 5 (Ad5) and the adenovirus serotype 35 
(Ad35) have been used in this study. The capsid of the Ad5/35.IR-E1A construct is 
derived from the Ad5 capsid combined with the fiber proteins of the serotype 35 which 
utilizes CD46 instead of CAR as the primary receptor (72, 82-84). 
Therefore a first quantification and comparison of the primary viral receptor presentation 
on human GBM cells had to be conducted to evaluate the potential ability of Ad5/35.IR 
vectors to infect GBM. Thus, we first compared the expression of CD46 and CAR on the 
GBM cell lines SF767, T98G and U-87 MG [Figure 13].  The flow-cytometric analysis of 
all three cell lines showed a higher mean fluorescence after incubation with anti-CD46
antibodies compared to incubation with anti-CAR. 
The mean fluorescence after incubation with the anti-CD46 antibody in a 1:100 dilution 
was >30 in all three cell lines, whereas the mean fluorescence after incubation with anti-
CAR did not exceed 4 in case of the cell lines U-87 MG and T98G. Only the cell line 
SF767 demonstrated comparatively high CAR expression, with a mean fluorescence of 
38. However, incubation with anti- CD46 results in a 4-fold higher mean fluorescence 
and shows that the SF767 cell line also presents higher CD46 levels, as compared to 
CAR levels. The detectable amounts of the CD46 receptor on the surface of human 
GBM cell lines correlate with the findings in the human colon carcinoma cell line (LoVo),
which was previously successfully transduced with Ad5/35.IR.E1A/TRAIL  (106).
In contrast to CAR, the expression of the group B receptor, CD46, was found to be 
upregulated in all tested GBM tumor cell lines. 
in vitro
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Figure 13:
36
 CD46 and CAR expression on human glioblastoma cells. Monolayer of SF767,U-87 MG, and 
T98G cells were analyzed for expression of the Ad35 wild-type and Ad5/Ad35.IR vector receptor CD46 and 
the Ad5 wild-type receptor CAR by surface labeling. Cells were harvested and incubated with anti-CAR or 
anti-CD46 monoclonal antibodies and a secondary FITC-labeled anti-mouse antibody. The labeled cells 
were analyzed by flow cytometry. The graphs represent fluorescence after incubation with different dilutions 
of anti-CAR (blue) or anti-CD46 (green) antibodies compared with an IgG-negative control (red shaded).  
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4.2 Ad5/35.IR-E1A/TRAIL shows efficient oncolytic effects in human 
GBM cell lines compared to Ad wild-type
37
To determine if the abundance of CD46 leads to an infective advantage of Ad35 vectors
over Ad5, infectivity and cell killing has been compared with the adenoviral vectors wild-
type serotype 5 (Ad5), wild-type serotype 35 (Ad35) and Ad5/35.IR-E1A/TRAIL. In 
addition Ad5/35.IR-E1A/GFP was added to compare the oncolytic activity of TRAIL in 
case of the chimeric Ad5/35 vector.  In the Ad5/35.IR-E1A/GFP vector, the transgene 
TRAIL has been exchanged with GFP, thus any observed enhanced oncolysis can be 
credited to the tumor cell killing abilities of TRAIL.  
Human GBM cell lines SF767, U-87 MG and T98G were infected with an MOI of 1 and 
observed for occurring oncolysis over a time period of  6 days after infection [Figure 14].
In addition T98G were infected with the same vectors using an MOI of 10 after an initial 
experiment with an MOI of 1 showed only minimal impact on this cell line . 
 infection of the human GBM cell lines with an MOI of 1 resulted in a more 
efficient tumor cell killing of the TRAIL expressing oncolytic vector compared to GBM 
cells infected with the adenoviral wild-types and the adenoviral construct Ad5/35.IR-
E1A/GFP. 
The TRAIL expressing vector began to show induction of cell death in 80% of the 
infected SF767 cells 3 days post infection (dpi) while approximately only 10% - 15% cell 
death occurred in Ad35 infected cells. Beginning significant cell killing, as compared to 
mock-infected cells, in Ad35 infected SF767 can be observed after 5 dpi. Ad5 does not 
have the ability to induce apoptosis in SF767 within the first 6 days after infection with an 
MOI of 1. 
U-87 cells are lyzed by Ad5/35.IR-E1A/TRAIL by up to 90% within 5 days while no 
complete cell killing can be achieved with wild-type virus or an Ad5/35.IR-E1A construct 
without TRAIL within 6 days.
In vitro
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Figure 14
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: Oncolytic effect of Ad5/Ad35.IR-E1A/TRAIL. Confluent monolayers of the GBM cell lines U-87 
MG (A + A1), SF767 (B + B1),and T98G (C + C1) were grown in a 24-well cell culture dish for the crystal 
violet assay and a 48-well dish for the MTT assay. The cells were infected with Ad5,Ad35, Ad5/Ad35.IR -
E1A/GFP (Ad5/Ad35-GFP), or the oncolytic vector Ad5/Ad35.IR-E1A/TRAIL (Ad5/Ad35-T) with an MOI of 1 
pfu/cell for each assay. In addition, confluent T98G monolayers were infected with a MOI of 10 pfu/cell (D). 
One well per viral infection was fixed in 4% PFA every 24 h, and the viable cells were visualized by staining 
with crystal violet. For the MTT assay, MTT was added to the wells of the infected cell lines everyday. After 
3 h incubation, the formazan product was analyzed.
The T98G glioblastoma cell line showed a higher resistance to viral oncolysis in general.  
Beginning cellular lysis was detectable 4 dpi after infection with Ad5/35.IR-E1A/TRAIL. 
However only 15% - 20% cell killing can be shown in T98G cells after infection with 
Ad5/35.IR-E1A/TRAIL, while Ad5 and Ad35 show no detectable cell lysis at the same 
time point. Infection of T98G cells with an MOI of 10 showed that adenoviral serotypes 5 
and 35 are generally capable of inducing cell death in the cell line T98G within 6 days 
after infection, although with only minimal effect. Ad5/35.IR-E1A/TRAIL on the other 





.  (MOI of 1 pfu/cell) (MOI of 1 pfu/cell) 
(MOI of 1 pfu/cell) (MOI of 10 pfus/cell)
                                                                                          4. RESULTS
4.3 Examination of the observed reduced & delayed cell killing in
T98G cells compared to the SF767 and U-87 MG cell lines via Q-PCR
39
The results show that compared to Ad5 wild-type, Ad35 vectors feature a slightly 
enhanced ability to infect GBM cells and induce cell killing.  Expression of the transgene 
TRAIL results in a significantly enhanced tumor cell killing all three GBM cell lines 
examined in this study.
The observed resistance to adenoviral-mediated oncolysis, including Ad5/35.IR-
E1A/TRAIL, of the human GBM cell line T98G was further examined via quantitative 
PCR.  In a comparative Q-PCR setting U-87 MG and T98G cells were transduced with 
an MOI of 100 using Ad5/35.IR-E1A/TRAIL or Ad5/35.IR-E1A/GFP. 
Three hours post infection the amount of intracellular viral DNA was quantified, followed 
by a second quantification 72 hours post infection using primers with binding sites within 
the viral gene  and the cellular housekeeping gene in case of the cells 
[Figure 15].  Dilutions of ascertained adenoviral genomes and GBM cells were used as a 
standard for the quantitative PCR.
Analysis of GBM cells 3 hours post infection showed a small number of viral genome 
copies in U-87 and T98G cells proving that Ad5/35-constructs are generally capable of 
infecting T98G cells as well as U87-MG . In direct comparison however twice as 
many viral genomes could be detected on average in U-87 MG cells after infection with 
Ad5/35- vectors compared to T98G at the same time point post-infection [Figure 15 A]. 
After 72 hours the gap between detectable viral copy numbers in the two cell lines was 
greatly increased by 8-10 fold in cells transduced with Ad5/35 vectors [Figure 15, B1 + 
B2]. This leads to the conclusion that initially reduced viral vector delivery leads to 
reduced numbers of viral copies in T98G cells which results in detection of less 
synthesized viral genomes. However the significant difference in detectable viral copies 
E1A HPRT1 
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Figure15: 
4.4  A U-87 MG stem-like cell sub-population forms tumor spheres 
that can be efficiently transduced and lyzed by Ad5/35.IR-E1A/TRAIL 
infection   
40
per cell in a time frame that resembles a complete infection cycle indicates impaired
adenoviral DNA synthesis in case of T98G cells as well. 
Comparative quantitative real time PCR of transduced human GBM cell lines U-87 MG and 
T98G:  U-87 MG or T98G cells were transduced with an MOI of 100 using Ad5/35.IR-E1A/TRAIL or 
Ad5/35.IR-E1A/GFP. Cellular DNA was detected via the housekeeping gene and intracellular viral 
DNA was quantified using the viral gene , located within the viral expression cassette. A standard was 
prepared using dilutions of adenoviral and cellular genomes. Samples were quantified 3 and 72 hours post 
initial viral transduction. 
It had been proposed that a minor sub-population of cancer stem cells (CSCs) derived 
from glioblastoma tumor tissue exists in human cell lines available, and may be 
maintained even in FBS containing medium.  CSCs from different tumor cell lines have 
been isolated either by utilizing the expression of the stem cell marker CD133 or on the 
basis of their ability to exclude the fluorescent vital dye Hoechst 33342 (107-109).  A 
distinct "sub population" of U-87 MG cells that has the ability to form “non-physiological 
tumorspheres”  has also been found and characterized (110).
We were able to verify the existence of this sub population in the U-87 MG cell line 








































 U-87 MG sub-population positive for stem cell marker CD133 in a non CSC-enriched 
culture and the morphology of  tumor stem cell spheres via light microscopy. (A) Primary U-87 MG 
neurosphere grown in culture “non-physiological” as reported by Shi-Cang Yu et al.(110) were 
morphologically comparable with our tumorspheres formed from U-87 MG cells in non-selective medium (B). 
(C) Advanced oncolysis of a U-87 MG sphere 6 days post  infection with Ad5/35.IR-E1A/TRAIL at an 
MOI of 1. 
We detected a subpopulation of approximately 0.25% cells expressing the marker 
CD133 within  cell cultures with FBS and a non CSC-enriching setting.  Growth of 
low passage, low density U-87 MG cells in cell culture lead to the  growth of 
tumorspheres morphologically identical to the cancer stem cell neurospheres as 
reported by Shi-Cang Yu et al. [Figure 16].
 infection of these neurospheres with wild-type adenoviruses result in no visible 
cell lysis within the tumorspheres 6 dpi while cells infected with  Ad5/35.IR-E1A/TRAIL at 
the same MOI exhibit clearly apoptotic features and cellular lysis of the tumorspheres 







                                                                                          4. RESULTS
Figure 17:
4.5 Ad5/35.IR-E1A/TRAIL shows an enhanced spread in U-87 MG 
plaque assays compared to wild-type adenovirus 
Mock Ad5 wt Ad35 wt Ad5/35.IR-E1A/TRAIL
42
 U-87 MG neurosphere infected at an MOI of 1 with wild-type virus serotype 5 (Ad5 wt), wild-type 
virus serotype 35 (Ad35 wt) or the Ad5/35.IR-E1A/TRAIL vector 6 days post infection. Wild-type infected 
cells show no signs of significant cell killing. Only Ad5/35.IR-E1A/TRAIL has a significant oncolytic impact on 
the tumorspheres compared to mock infected cells. 
In addition to the observed enhanced cell killing effect  we wanted to examine if  
the shifted tropism of the vector Ad5/35.IR-E1A/TRAIL in combination with the apoptosis 
inducing transgene leads to an enhanced viral spread in GBM tissue compared to either 
Ad serotype 5 wild-type or Ad serotype 35 wild-type which features the same receptor 
but lacks the expression of an oncolytic transgene.  
U-87 MG cells were infected with approximately 50 to 100 pfu of each virus and an 
agarose overlay was added to limit newly generated particles to localized cell-to-cell 
spread. The resulting plaque development of infected cells was observed over several 
days [Figure 18]. 
After 9 days most U-87 MG cells initially transduced with Ad35, featured plaques that 
were slightly enhanced in size compared to the serotype 5 wild-type which can be 
attributed to the lack of the primary receptor CAR.  The absence of the primary receptor
leads to an inhibition of the viral spread in case of Ad5 although it does not inhibit viral 
transduction completely. 
in vitro
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Figure 18:
4.6 Ad5/35.IR-E1A/TRAIL mediates enhanced induction of apoptosis 
in human GBM cells compared to adenoviral wild-type virus. 
mock Ad5 wt Ad35 wt Ad5/35-TRAIL
43
EA4 0.10/160 -EA4 .10/160 -
 Plaque assay. Confluent U-87 monolayers were infected with 50-100 pfu of wild-type Adenovirus 
serotype 5 or 35 (Ad5 wt, Ad35 wt) or Ad5/35.IR-E1A/TRAIL (Ad5/35-TRAIL). The cells  received a 1% 
agarose overlay and the plaque development was monitored for 9 days. Plaques resulting from Ad5/35.IR-
E1A/TRAIL infection were approximately 3-6 times larger compared to wild-type virus plaques.
However, Ad5/35.IR-E1A/TRAIL showed plaques sized 3-6 times larger compared to 
those infected with Ad5 or Ad35. This indicates that after human GBM transduction 
TRAIL expression and resulting apoptosis leads to fast cell lysis and release of 
produced viral particles which, in turn, accelerates the viral spread within a GBM cell 
monolayer .    
This correlates with former reports that TRAIL expressing adenoviral vectors have the 
ability to release  produced virus from infected cells  and cause a 
significant bystander effect and verifies that this is also a given feature in human 
glioblastoma cells (77).
Cell killing assays did prove that the human GBM cell lines U-87 MG, T98G, and SF767 
are sensitive to Ad5/Ad35.IR-E1A/TRAIL. In order to assess if the cell killing can be 
attributed to TRAIL-mediated apoptosis, infected cells were examined with a TUNEL
assay at fixed time points after primary transduction [Figure 19]. 
de novo
in vitro
de novo in vitro
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The TUNEL assay is an  cell death detection assay that detects cells undergoing 
apoptosis by labeling free 3’-OH termini of the cellular DNA fragments that are a result of 
the DNA fragmentation during the final phase of apoptosis. 
In addition to examining the apoptosis-inducing potential of the Ad5/35.IR-E1A/TRAIL, a 
direct comparison of the effect of the Ad5/35 capsid as a gene delivery vehicle with wild-
type serotype 5 was to be tested. For this, it was necessary to compare the vector 
Ad5/35.IR-E1A/TRAIL with Ad5.IR-E1A/TRAIL which expresses TRAIL in the same 
manner as Ad5/35.IR-E1A/TRAIL but does not feature the Ad35 fiber and therefore 
relies on CAR as the primary receptor. 
To monitor the apoptotic features of a wild-type virus lacking any oncolytic transgenes, 
the adenoviral serotype 35 was used. The cell lines were infected with an MOI of 1 
pfu/cell and observed for 4 days for virus-mediated induction of apoptosis. We found that 
25% to 50% of the cultured human GBM cells from SF767 or U-87 MG were positive by 
TUNEL assay 4 days after infection with Ad5/35.IR-E1A/TRAIL or Ad5.IR-E1A/TRAIL, 
whereas wild-type virus showed no significant increase in TUNEL-positive cells 
compared with mock-infected GBM cultures. 
Elevated levels of apoptosis were detectable in T98G cells after infection with Ad5/35.IR-
E1A/TRAIL but not Ad35 or Ad5.IR-E1A/TRAIL. Direct comparison of Ad5.IR-E1A/TRAIL 
and Ad5/35.IR.E1A/TRAIL via TUNEL assay shows that, in SF767 and T98G, 20% to 
30% more cells seem apoptosis-positive 4 days after infection with 
Ad5/Ad35.IR.E1A/TRAIL, whereas this difference can be already observed after 2 days 
in U-87 MG cells.
in situ
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Figure 19:
4.7 Comparison of the transduction abilities of chimeric adenoviral 
vectors composed of the serotye 5 capsid with either serotype 35 or 
serotype 11 fiber protein   
SF767














































































































 Apoptosis induction in human glioblastoma cell lines SF767, T98G, and U-87 MG after infection 
with Ad5/Ad35.IR-E1A/TRAIL (Ad5/35-T), Ad5.IR-E1A/TRAIL (Ad5-T), or Ad35 with an MOI of 1 pfu/cell. 
Wells of each cell line were harvested  48 h post infection (A) and 96 h post infection (B). Induced apoptosis 
was detected via visualization of occurred DNA fragmentation by FITC labeling of free 3’-OH termini with an
 cell death detection kit. The cells were analyzed using flow cytometry.
Our findings show that the chimeric Ad5/35 vector with the serotype 35 fiber has 
superior transduction abilities compared to Ad5 wild-type which is most likely due to a 
high expression of the serotype 35 receptor CD46 on GBM cells. 
 However we have also observed that the transduction efficacy of Ad5/35 can vary in 
different human GBM cell lines. The diminished killing of T98G cells by Ad5/35 in 
combination with the finding that only half the number of viral copies can be found after 
transduction compared to other cell lines, support this observation.   
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Figure 20: 
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CD46 as well as an unidentified receptor glycoprotein which is is abundantly expressed 
at high levels on human mesenchymal and undifferentiated embryonic stem cells, as 
well as on human cancer cell lines (111) [Figure 20] 
Group III adenoviruses (Ad11p) utilize CD46 alternative
target receptor X for binding target cells
Incorporation of fiber protein/knob 11 might improve the transduction efficacy of human 
GBM cells and most importantly GBM cancer stem cells. Therefore we wanted to 
compare the transduction abilities of a Ad5/35 vector with a vector composed of the 
serotype 5 capsid with the fiber protein of serotype 11.  For this we transduced the cell 
lines U-87 MG and T98G 
with the chimeric vector Ad5/35 or Ad5/11, both expressing GFP, at MOIs of 0.1 or 1
respectively .
48 hours post transduction the cells were harvested and examined for GFP expression 
using flow cytometry.  Vector Ad5/11 was able to transduce both cell lines successfully
and shows a twofold increase of infected U-87 MG and T98G cells compared to Ad5/35
[Figure 21].
in vitro
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Figure 21:
4.8  test of Ad5/Ad35.IR-E1A/TRAIL by generating a 





























































 Higher infectivity of Ad5/11 vectors compared to Ad5/35. Human GBM cell lines U-87 MG and 
T98G were transduced with either Ad5/35- or Ad5/11 vectors expressing GFP at an MOI of 0.1 or 1. Cells 
were harvested and analyzed for GFP expression via flow cytometry 48 hours post transduction. A two- to 
threefold increase of successfully transduced cell gated positive for GFP could be observed in case of the 
Ad5/11 vector. 
For a tumor  model human U-87 MG GBM cells were mixed with solubilized 
basement membrane (MatrigelTM) and subcutaneously injected into the flanks of 
NOD/SCID mice. This did result in the subcutaneous growth of human GBM tumors of
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The model was used first to evaluate if 
intratumoral injection of Ad5/35.IR-
E1A/TRAIL leads to infection of tumor 
tissue, viral spread and TRAIL-mediated 
induction of apoptosis . Therefore
Ad5/35.IR-E1A/TRAIL or Ad35 wild-type 
were injected directly into subcutaneously 
growing tumor xenografts of U-87 MG cells 
in NOD/SCID mice. 
Two weeks after viral injection the mice 
were sacrificed and the tumor tissue was 
extracted, embedded in OCT-media and 
frozen. Tumor cryosections were then 
examined for areas of apoptotic tissue around the application site using the TUNEL 
assay [Figure 23].
Apoptotic tissue areas were found in tumors injected with Ad5/35.IR-E1A/TRAIL and 
Ad35 wild-type, while tumors injected with PBS showed no significant apoptotic/necrotic 
areas. Viral capsid hexon proteins were detected in the apoptotic areas using a goat 
Ad-hexon capsid protein antibody. Viral capsid protein was found within the apoptotic 
sections of the dissected tumor tissue in case of Ad5/35.IR-E1A/TRAIL and Ad35 
indicating that the induction of apoptosis in these regions was caused by the viral 
infection. In direct comparison, the tissue samples of the Ad5/35.IR-E1A/TRAIL vectors 
showed large apoptotic areas with elevated amounts of viral hexon capsid protein in 
case of Ad5/35.IR-E1A/TRAIL compared to tumor samples injected with Ad35.  
in vivo
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Figure 23:










 Induction of apoptosis in xenografted GBM tumors after intratumoral (i.t.) Ad5/Ad35.IR-
E1A/TRAIL application. U-87 cells (2 x 106) were mixed with Matrigel and injected subcutaneously (s.c.) into 
flanks of NOD/SCID mice. After tumors reached a size of 100 mm3, 1 x 108 pfu of the oncololytic adenovirus 
Ad5/Ad35.IR-E1A/TRAIL or Ad35 was injected i.t. Mice were sacrificed 2 weeks after viral application. The 
tumors were embedded in OCT and frozen. Dissected tumor tissue was analyzed for apoptosis/necrotic 
tissue using an  cell death detection kit (TUNEL assay, Roche; A) and viral hexon capsid proteins 
using goat a-adenovirus hexon antibody (B).
in situ
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4.9 Subcutaneous xenografts in NOD/SCID mice using human GBM 




After it was established that Ad5/35.IR-E1A/TRAIL was capable of infecting human GBM 
cells which resulted in viral spread and induction of apoptosis, the 
efficiency of Ad5/35.IR-E1A/TRAIL to cause reduction of tumor growth or even tumor 
recession had to be tested.  
In a first experiment U-87 MG cells were infected with Ad5/35.IR-E1A/TRAIL, Ad5/35.IR-
E1A/GFP, Ad5 or Ad35  using an MOI of 100 to ensure a 100% infection rate. 1 x 
106 uninfected U-87 MG cells were mixed with 1% infected cells and injected 
subcutaneously into NOD/SCID mice. The s.c. growth of the tumors was observed via 
size measurement every other day after injection of the cells. The size of the tumors 
containing virus was compared to the tumor growth of 1 x 106 untreated U-87 cells 
[Figure 24].
The tumors containing cells infected with Ad5/35.IR-E1A/TRAIL started to show growth 
impairment 8 days after subcutaneous injection with 40% less tumor volume compared 
to the negative control. The average growth of the tumors treated with Ad5/35.IR-
E1A/TRAIL remained reduced with approximately 40-50% volume size compared to the 
untreated tumors for the entire 20 day follow-up after injection. Slight impairment was 
also detectable in the size of Ad5, Ad35 and Ad5/35.IR-E1A/GFP treated tumors. 
However,these tumors grew faster compared to Ad5/35.IR-E1A/TRAIL and the growth 
impairment was not continuous significantly smaller as compared to the mock control in 
those three groups. 
Control tumor size and the size of Ad5/35.IR-E1A/TRAIL treated tumors was analyzed 
and compared using the Mann Whitney U Test showing that viral tumor growth 
impairment was significant 8 days after injection (P < 0.01, two-tailed test). A significant 
difference in size among untreated tumors and tumors treated with Ad5/35.IR-
E1A/TRAIL was confirmed for the entire 20 day follow-up after injection, while Ad35 and 
Ad5/35.IR-E1A/GFP treated tumors showed a significantly smaller average tumor 
in vivo in vivo
in vitro
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Figure 24:
4.10 Intratumoral injection of Ad5/35.IR-E1A/TRAIL into U-87 MG 
tumor xenografts in NOD/SCID mice 
51
volume only during a period of 4 days (P < 0.01, two-tailed test). Ad5 treated tumors 
showed no significant difference compared to the size of untreated tumors. 
 Measurement of the average tumor size after ex vivo virus application and s.c. xenografting in 
NOD/SCID mice. U-87 MG cells (1x106)  were mixed with 1% cells infected with Ad5, Ad35, Ad5/Ad35.IR-
E1A/GFP, or Ad5/Ad35.IR-E1A/TRAIL or uninfected cells as negative control (NeCo) and Matrigel, followed 
by s.c. injection into the flanks of NOD/SCID mice (n = 10). The tumor growth was monitored using a caliper
every other day.
To analyze if direct intratumoral application of Ad5/35.IR-E1A/TRAIL leads to similar 
effects in regard to tumor growth as observed in an   setting  Ad5, Ad35, 
Ad5/35.IR-E1A/GFP or Ad5/35.IR-E1A/TRAIL virus was injected intratumorally into 
xenografted U-87 MG tumors in athymic mice and compared to untreated tumors. After 
s.c. injection of 1x106 U-87 MG cells into both flanks of NOD/SCID the resulting tumor 

































































mm3. At this point 1 x 108 pfu of Ad5, Ad35, Ad5/35.IR-E1A/GFP or Ad5/35.IR-
E1A/TRAIL was injected intratumorally followed by a second injection of 1 x 108 pfu 48
hours later [Figure 25].
 Comparison of tumor average growth after i.t. injections of adenoviral wild-type Ad5, Ad 35,
Ad5/Ad35.IR-E1A/GFP, or Ad5/Ad35.IR-E1A/TRAIL into s.c. xenografted U-87 MG tumors. U-87 MG cells 
(1x106) in Matrigel were injected s.c. into the flanks of NOD/SCID mice. Tumor growth was monitored using 
a caliper. After the average tumor volume in each group (n = 10) reached 50 mm3 (+/-15%), 1 x108 pfu of 
Ad5, Ad35, Ad5/Ad35.IR-E1A/GFP, or Ad5/Ad35.IR-E1A/TRAIL or 10 µL PBS as a negative control (NeCo) 
were injected i.t. Another injection of 1x108 pfu followed 48 h later. The tumor growth was measured every 
other day using a caliper. Growth of the tumors is illustrated by comparison of the size of each tumor directly 
after viral treatment (100%) with the size at each following reading point of the tumor. Until day 10 post i.t. 
injection tumor growth was significantly reduced after Ad5/Ad35.IR-E1A/TRAIL injection (P < 0.01, two-tailed 
test).
While injection with the wild-type virus or the Ad5/35.IR-E1A/GFP virus led to no change 
in the tumor growth pattern compared to the untreated negative control, Ad5/35.IR-
E1A/TRAIL treated tumors grew less than 5% during the first 4 days after the second 
injection. Furthermore, the injection of Ad5/35.IR-E1A/TRAIL led to an average tumor 
growth that was significantly lower compared to the tumor growth of xenografts treated 
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with wild-type virus, Ad5/35.IR-E1A/GFP or untreated tumors until day 10 after viral 
injections (P < 0.01, two-tailed test).
To test if CD46 is also expressed at high levels in U-87 MG cells within the tumor 
human GBM cells were injected subcutaneously in NOD/SCID mice and the tumor 
xenograft was removed 3 weeks after injection. Tumor tissue was embedded in OCT 
and frozen. Cryosections were stained using a peroxidase-based visualization kit 
(EnVision system K1390) [Figure 26]
Sections were incubated with an anti-CD46 (mouse a- human) antibody, an MHC I 
antibody as positive control or IgG antibody as negative control. As expected, the MHC 
class 1 antigen was expressed abundantly within the tumor (112) while the mouse IgG 
Isotype control did not show any non-specific binding. Although the signal strength of the 
CD46 stained sections showed that MHC class 1 is expressed at higher levels, CD46 is 
still expressed in clearly detectable levels throughout the entire U87-MG tumor
Further examination of subcutaneously grown tumors using a lower magnification 
revealed that the centers of the tumors are largely necrotic, Furthermore staining for 
factors as CD46 revealed stroma-like areas with excessive amounts of extracellular 
matrix (ECM) proteins with only few GBM cells included. These stroma structures were 
found pervading throughout the tumor. This shows that the tissue is not homogenous but 
that the tumor composition is more likely a center of apoptotic tissue surrounded by 








 A. U-87 MG tumor sections stained for CD46. 
OCT embedded cryosections were analyzed for 
CD46 expression. Sections were incubated with a-CD46 
(mouse a- human) antibody, a- IgG as negative control and 
a- (MHC)I as positive control followed by treatment with 
chromagen. Staining was performed using Dako “K1390 
Envision system, peroxidase” and the slides were 
counterstained with Gill’s (blue).
B. A 10 x magnification of a CD46 stained representive 
section of GBM tumor tissue. Low magnification reveals a 
heterologous structure of tumor tissue featuring areas of 
dense tumor cell layers with abundant CD46 (1) which are 
pervaded by egions of ECM/stroma protein with only few 
insular tumor cells (2). 
in vivo




Here we examined the efficacy of a novel oncolytic adenoviral vector Ad5/35.IR-
E1A/TRAIL for the treatment of GBM. We performed a variety of experiments to analyze 
and compare the effects of Ad5/35.IR-E1A/TRAIL with other adenoviral vectors. 
The Ad5/35.IR-E1A/TRAIL primary receptor CD46 was detectable on all three human 
GBM cell lines. All 3 cell lines showed more expression of the CD46 than the CAR 
receptor which is used by the Ad5 serotype. [Figure13].
We show that that chimeric vectors were able to transduce all three tested GBM cell 
lines. Comparison of the two chimeric capsids Ad5/11 and Ad5/35 showed that the 
transduction efficacy is two fold higher in case of Ad5/11 chimeric vectors in U-87 MG 
and T98G GBM cell lines [Figure 21]. Our experiments confirmed that utilization of 
Ad5/35.IR-E1A/TRAIL resulted in an increased transduction rate and oncolytic activity as 
compared to wild-type virus in all the three GBM cell lines. [Figure 14] .
We found that infection of SF767 and U-87 MG cells with Ad5/Ad35.IR-E1A/TRAIL leads 
to rapid TRAIL-mediated induction of apoptosis as compared to cells treated with wild-
type virus.  Specifically U87-MG cells proved to be very susceptible to Ad5.IR-
E1A/TRAIL transduction and TRAIL induced apoptosis.
The superior viral oncolytic features of Ad5/35.IR-E1A/TRAIL were also observed 
in two different experimental  settings. Significant tumor growth reduction was 
observed in case of treatment with Ad5/35.IR-E1A/TRAIL as compared to wild-type 
adenovirus or Ad5/35.IR constructs without TRAIL expression [Figure24, Figure 25].
in vitro 
in vivo
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Viral gene therapy is generally limited by the presence of sufficient amounts of the 
essential viral receptors. Recently the receptor for the adenoviral serotype Ad35 has 
been shown to be CD46 (77). Examination and comparative quantification of the 
serotype Ad35 receptor CD46 with the Ad5 wild-type CAR receptor was performed, to 
shed light on the general surface composition of GBM cells in case of the primary 
receptors. 
The primary receptor levels are of major importance as their surface presentation should 
correlate directly with viral transduction ability and targeting in vivo while it can be 
considered advantageous if the expression levels in healthy brain tissue are low to 
further avoid any viral uptake in non-GBM cells. The serotype 5 primary receptor CAR is 
expressed during fetal development particularly in brain and muscle (113, 114, 115).
Expression is diminishing during the neonatal period and the developing brain has been 
shown to express increased CAR compared to the adult brain of mice (114).  CAR 
mRNA levels were highest near birth and diminished thereafter. Furthermore CAR can 
also be detected in epithelial cells of embryonic liver, lung, heart, eye, digestive system, 
pancreas, kidney, and the submandibular glands (116). A rapid downregulation of CAR 
occurs at birth, after which CAR is only sparsely detected in most of these tissues as 
well. CAR is an immunoglobulin-like single-spanning transmembrane intercellular 
adhesion molecule that has an essential function in development. Besides CAR's role as 
viral receptor, its physiological and pathological functions remain unclear. It is known 
that CAR is both a regulator of the Notch signaling pathway (117,118) with roles in 
embryonic development, and an epithelial intercellular adhesion molecule with reported 
contributions to mucosal integrity and barrier function (119,120). Furthermore, functional 
analogies of CAR to E-cadherin or E-selectin have been suggested (116, 121).  CAR’s 
role in tumor engraftment and malignancy and its mechanism underlying this role is still 
somewhat elusive.  Imaging analysis localized CAR in tight junctions of T-84 colon 
cancer cells (115), or in the adherent junctions in A549 lung cancer cells (116). In case 
of prostate cancer it has been suggested that high CAR levels diminish with increasing 
grade of primary prostate cancer while the receptor re-emergences in metastases (122).
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But in contrast to this, another study examined breast cancer tissues and demonstrated 
that elevated CAR expression correlate with an increasing tumor grade (123).  
However many groups reported that overall CAR expression seems to be reduced on 
the cellular surface of malignant tumors of different types of cancers (81, 83+84, 124-
126). More importantly it has been shown that mean values of CAR expression in 
primary GBM tissues are significantly lower as compared to primary lower grade tumors 
(127). This implies that, in case of GBM, CAR is further down-regulated during tumor 
progression from low-grade astrocytomas to GBM. Similar findings have been reported 
for different tumor types and it has been suggested that CAR could be down-regulated 
due to its adhesive and tumor-suppressive functions (128, 129).  This correlates with our 
observation of general low expression of the CAR receptor in case of all examined GBM 
cell lines. This does suggest the down-regulation of CAR as a potential tumor 
suppressor in human GBM. These findings render human GBM as a high grade glioma 
unattractive for treatment with the commonly used Ad5 vector due to the lack of the 
primary receptor for this serotype on high-grade glioma. 
On the other hand all examined cell lines were strongly positive for CD46, comparable 
with findings in other tumor cell lines (21).  As opposed to CAR, the function of the 
complement regulatory protein CD46 as a membrane-bound complement inhibitor is well 
understood. The type I membrane protein is a regulatory part of the complement system
and has cofactor activity for inactivation of complement components C3b and C4b by 
serum factor I, which protects the host cell from damage by complement (130). 
CD46 is frequently overexpressed in tumor cells, serving as a mechanism of tumor cell 
protection against complement-mediated lysis (131+132). Membrane-associated 
complement regulatory proteins, such as CD46 play an important role in cellular self 
protection as they have the ability to render cells insensitive to the action of complement. 
It has been shown that resistance of tumor cells to complement-mediated lysis depends 
on these complement regulatory proteins which appear to be over-expressed on a 
variety of tumors and provide tumor cells with extracellular protection. Therefore CD46 
can be found in high levels on a variety of tumors including human glioma. In normal 
brain tissue and the blood–brain barrier CD46 has been reported to be ubiquitous 
detectable, although only in low levels (133, 1134). This does make CD46 a good 
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candidate as a primary receptor for an oncolytic virus since a comprehensive source of 
the primary receptor targets the vector to GBM cancer cells while spreading from the 
tumor site is impeded by low levels in healthy tissue surrounding the tumor tissue. 
Different attempts have already been made to identify viruses that preferentially infect 
tumor cells that overexpress receptors for virus entry or to genetically engineer viral 
vectors with those abilities (135). With our Ad5/35.IR vector we reach this goal by 
utilizing the fiber protein of an adenovirus that binds to CD46 in order to create modified 
serotype 5 capsids to change the adenoviral vector tropism in order to circumvent the 
observed CAR deficiency of GBM. 
Furthermore it has been shown that vectors utilizing CD46 as cellular receptor, 
transduce malignant tumor cells like LoVo more efficiently compared to wild-type virus 
(77). In addition the shifted tropism of the vector Ad5/35.IR-E1A/TRAIL has already been 
proven to enhance the viral oncolytic effect of the virus  (77).  
 transduction of GBM cell lines with low MOIs showed that chimeric vectors were 
able to transduce the three tested GBM cell lines. However, since cell lines exhibit 
different sensitivities to Ad5/Ad35.IR-E1A/TRAIL-mediated cell killing we assume that 
the transduction ability of the vector does vary. Infection with wild-type Ad5 resulted in 
no or only little cell killing in GBM monolayers . This was expected because it has 
been reported that the Ad5 virus does not transduce neural cells effectively (38).
Interestingly, we did observe some transduction and cell killing in case of U-87 MG and 
T98G cells with Ad5 even though we were not able to detect any CAR expression in 
these cell lines [Figure 13] . 
This indicates that the primary receptor expression pattern might not result in a particular 
difference in case of  experiments as even without the primary receptor, serotype 
5 capsids seem to be able are able to directly interact with cellular avß3/avß5 integrins 
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type serotype 5 transduction of U-87 MG or T98G cells, even though they do not seem 
to feature the CAR receptor. This correlates with a previous  study showing that  
primary receptor levels do not translate into correspondingly higher transduction 
efficiencies in case of Ad5/35 chimeric vectors (136).  
An interesting observation supporting this theory has been the inefficient cell lysis of the 
serotype Ad35 and the vector Ad5/Ad35.IR-E1A/GFP in T98G cells and the reduced cell 
killing of U-87 MG and SF767 cells compared directly to Ad5/35.IR-E1A/TRAIL [Figure 
14]. This does suggest that the increased oncolytic ability of the Ad5/35.IR-E1A/TRAIL 
vector is not caused by the use of the chimeric Ad5/35 capsid but that the apoptosis-
inducing gene TRAIL plays a key role in cell killing of GBM cells after infection with 
Ad5/35.IR-E1A/TRAIL.  tests of viral tumor penetration after  transduction 
on the other hand showed that the primary receptor is of importance for the viral vector 
as serotype 5 vectors showed the least effect on tumor growth in both murine xenograft 
models [Figure 24, Figure 25]. In fact only a vector with the chimeric 5/35 capsid and 
TRAIL expression was able to show a significant impact after  application.    
Therefore our findings indicate that the vector Ad5/35.IR-E1A/TRAIL, utilizing the Ad35 
fiber protein, features an evident advantage over adenoviral vectors that use the 
serotype 5 fiber concerning the treatment of glioblastoma cells  due to its 
enhanced ability to infect human GBM cells.
The outcome of comparison between subgroup B fibers of serotype 35 and serotype 11 
by comparing Ad5/11 and Ad5/35 chimeric capsids [Figure 21] suggests that it could be 
beneficial to create and utilize an Ad5/11 oncolytic construct for future studies of the 
vector as it seems to be the most adequate vector for GBM transduction.
Both serotypes utilize the same receptor CD46 as a high-affinity attachment receptor 
(137).  Although both serotypes have an equivalent CD46 binding efficiency, Ad11 
features the additional opportunity to utilize the alternative receptor X, a yet unidentified 
receptor, via its fiber knob (138). Receptor X is expressed at high levels on human 
mesenchymal and undifferentiated embryonic stem cells, as well as on human cancer 
cell lines. It is of particular interest that Ad11 can use two receptors that are both present 
at high levels on tumor cells which potentially reduces the risk of escape mutants 
in vitro
In vivo ex vivo
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development by receptor-downregulation.  However a recent study showed that Ad5/11 
vectors were inferior to Ad5/35 chimeric vectors in pancreatic and breast cancer (139).  
Furthermore a comparison of transduction abilities from different adenoviral subgroups 
have proven that even if the particles bind to the same receptor , Ad serotypes
prove act differently  (140). Therefore it will be necessary to compare directly 
Ad5/35 chimeric vectors with Ad5/11 constructs  in a GBM tumor model to 
evaluate  transduction- and tumor penetration  abilities.   
Another important feature of the adenoviral vector is the expression of TRAIL. The 
utilization of TRAIL in different therapeutic approaches has been shown to induce 
apoptosis in a broad spectrum of different cancer types (141-143).
TRAIL has been shown to be a potent inducer of apoptosis in tumor cells which are far 
more susceptible to TRAIL than normal cells. Furthermore TRAIL mediated induction of 
apoptosis is independent of  expression or functionality. This is an important feature 
as p53 can be inactivated in human GBM tumors (144).  TRAIL molecules do not induce 
severe toxicities as for example expression of the Fas ligand CD95L does which is an 
additional advantage with regard to the usefulness of the transgene in a clinical setting 
 case of glioblastoma TRAIL has been shown to remain effective as a non-
modified ligand in the absence of any neurotoxicity in an   rodent model (146). The 
extensive TRAIL research with mainly promising results in case of GBM treatment 
indicates that this molecule can make a positive clinical contribution. In fact, translation 
of the preclinical TRAIL studies into the clinic has started already (147).
TRAIL expression using the Ad5/35.IR-E1A vector has also been proven to lead to 
effective oncolysis of human colon carcinoma cells in vitro compared to wild-type virus 
and control vectors (77). In this study our experiments confirmed that Ad5/35.IR-
E1A/TRAIL resulted in an increased transduction rate and oncolytic activity in all the 
three GBM cell lines while Ad5 had no or only little impact on infected GBM monolayers 
[Figure 14]. The vector showed a similarly enhanced effectiveness in oncolysis as seen 
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Ad5 transduction resulted in no or only little oncolysis due to its poor transduction abilites
(148). At the same time serotype Ad35 and the construct Ad5/35.IR-E1A/GFP showed 
also efficient cell lysis of T98G cells and only reduced cell killing after infection of U87-
MG and SF767. This observation suggests that the elevated oncolytic ability of 
Ad5/35.IR-E1A/TRAIL is not mainly due to the composition of a serotype 5 capsid with 
serotype 35 fiber proteins but that the major factor of the efficient cell killing is the 
expression of the apoptosis inducing transgene TRAIL. We hypothesize that the 
adenoviral expression leads to intracellular levels TRAIL capable of triggering the  
apoptosis mechanism eventually. This correlates with the hypothesis by Rieger et al.
who found that gliomas preferentially express the agonistic receptors but only small 
amounts of TRAIL itself.  From this they conclude that the presence of ligand and 
receptor at the cell surface is not enough to result in significant levels of apoptosis in 
 However intracellular overexpression of TRAIL ,as it is the case in cells 
transduced with Ad5/35.IR-E1A/TRAIL, leads to sufficient TRAIL levels to tip the balance 
and eventually induce apoptosis in the infected human GBM cell. 
  
We also observed a difference in the cell killing kinetics between the different cell lines 
which might have been caused by different expression levels of the cognate receptor
DR4 as described elsewhere (150). In fact multiple factors that lead to TRAIL resistance 
via upregulation of inhibitors, like expression of anti-apoptotic proteins, have been 
reported in a variety of different cancer types (151,152).  
 Since we observed that infection of the fairly apoptosis-resistant cell line T98G with a 
higher MOI showed improved cell killing abilities of the wild-types and Ad5/35.IR-
E1A/GFP but only marginally accelerated oncolysis of the vector expressing the 
transgene TRAIL, we come to the conclusion that impaired viral transduction is not the 
main reason leading to the observed resistance.   This rather suggests  that the oncolytic 
effect of a TRAIL-expressing viral vector is not proportionally enhanced by the elevation 
of viral titers. In fact, T98G resistance to TRAIL might be the main reason for the 
observed effect as it has been shown that the T98G cell line features strong 
phosphorylation of p68 which mediates resistance to TRAIL by procaspase-8 cleavage 
inhibition and furthermore causes cell proliferation, and epithelial–mesenchymal 
transition (EMT) (153).
tumors (149).
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 detection of apoptosis induced in SF767 and U-87 MG cells by Ad5/35.IR-
E1A/TRAIL using a TUNEL assay supported the findings from the cytotoxicity assay 
[Figure19]. Separate studies have shown that administration of human TRAIL induces 
apoptosis in human GBM cells (154,155),. Here we show via i  detection of 
apoptosis using a TUNEL assay that TRAIL expression in an adenoviral context leads to 
induction of apoptosis in all tested human GBM cell lines. Altogether we observed that 
infection of SF767 and U-87 MG cells with Ad5/35.IR-E1A/TRAIL leads to rapid induction 
of apoptosis compared with cells treated with the wild-type Ad35.
These findings show that replication of wild-type adenoviruses alone has only a minor 
effect on apoptosis induction and cell killing in human GBM cells whereas the additional 
expression of the transgene TRAIL significantly increases apoptosis. Comparison of the 
apoptosis inducing features of Ad5/35.IR-E1A/TRAIL and Ad5.IR-E1A/TRAIL show that 
the switch to the serotype 35 fiber protein generally enhances the transduction efficiency
of glioblastoma cells as it was to be expected from the primary receptor levels we found 
on human GBM. 
It has been demonstrated that Ad5/35.IR-E1A/TRAIL after completion of virion 
assembly facilitates the release of de novo produced virus from infected cells in HeLa, 
293 and transformed human embryonic kidney cells  which indicates the 
possibility of enhanced viral spread in tumors (77,156).
To test for similar effects in human GBM cells, U-87 MG cells where transduced 
with wild-type virus and the Ad5/35.IR-E1A/TRAIL vector. We observed that infection of 
monolayers followed by the addition of an agarose overlay leads also to larger plaque 
formations compared to the wild-type in U-87 MG cells after Ad5/35.IR-E1A/TRAIL 
infection [Figure 18]. This indicates a change of the kinetics of the infection cycle in GBM 
due to the expression of TRAIL. The significantly enhanced spread in tumor cells 
in vitro in vivo
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in human glioblastoma cells can be explained by the release of  produced viral 
particles due to TRAIL-mediated apoptosis comparatively early in the adenoviral 
infection cycle, which in turn leads to quicker spreading of viral particles. 
To examine if the enhanced viral spread of Ad5/35.IR-E1A/TRAIL can also be 
observed  after injections of CD46-dependent Ad35 wild-type virus and Ad5/35.IR-
E1A/TRAIL, 1 x 108 pfu of the oncolytic adenovirus Ad5/Ad35.IR-E1A/TRAIL or Ad35 
was injected intratumorally into subcutaneously xenografted U-87 MG tumors [Figure 
23].  
The tumor was removed 2 weeks after injection, dissected and analyzed for apoptosis 
by TUNEL assay and additionally for viral capsid proteins via an anti- adenovirus hexon 
antibody. Detectable expression of adenoviral capsid proteins and identification of 
apoptotic cells in the same areas of microdissected tumor tissue via TUNEL assay 
showed that the viral infection spreads efficiently and that the virus is able to induce 
apoptosis in infected cells .  The large apoptotic areas we found and the detection 
of higher amounts of viral capsid proteins compared to Ad 35 infected tumor tissue 
indicates that the TRAIL bystander effect could not only be a detectable factor 
but also be responsible for a significantly enhanced viral spread and enhanced capability 
of tumor tissue penetration after application of Ad5/35.IR-E1A/TRAIL in GBM tumors 
.
The most obvious difference in the oncolytic potential of the vector Ad5/35.IR-
E1A/TRAIL compared to wild-type or Ad5/35.IR-vectors that do not express TRAIL was 
observed using  assays.  Virus-mediated enhanced oncolysis and spread have 
already been shown in an  model in which a TRAIL expressing adenoviral vector 
was applied via tail vein infusion in immunodeficient CB17 mice. Those mice were  
carrying liver metastases induced by LoVo cell infusion which were  significantly reduced 
after application of Ad5/35.IR-E1A/TRAIL compared to the control vectors (77).
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tumors growing  leads to intratumoral spread and tumor growth reduction 
compared to the growth of untreated or wild-type treated tumors. 
To test this in a first model we mixed U-87 MG cells with 1% adenovirally pre-transduced 
U-87 MG cells prior to subcutaneous injection. Only Ad5/35.IR-E1A/TRAIL showed 
significant growth impairment over a period of 3 weeks [Figure 24]. We conclude that, as  
already observed  not the adenoviral vector but the viral TRAIL expression is 
primarily responsible for tumor growth reduction and tumor invasion.
Direct intratumoral injection of viral particles into xenografted solid U-87 MG tumors in 
NOD/SCID mice support these findings and show an even more distinct 
difference between wild-type virus, Ad5/35.IR-E1A - constructs lacking TRAIL 
expression and Ad5/35.IR-E1A/TRAIL. While injection of Ad5, Ad35 and Ad5/35.IR-
E1A/GFP into solid subcutaneous tumors showed no effect after intratumoral injection,
Ad5/35.IR-E1A/TRAIL exhibited the ability to nearly inhibit further tumor growth for 4 
days after viral injection and reduces tumor growth significantly for 10 days [Figure 25 ]. 
We propose that the combined E1A expression with TRAIL does lead to significantly 
enhanced induction of apoptosis in human GBM tumor tissue and that TRAIL expression 
of the viral Ad5/35.IR construct leads to a comparatively rapid induction of cell death in 
solid tumors after  application, which enables further intratumoral viral spread.
These results correlate with the observations we made after infecting cells ro. The 
ability to spread throughout the tumor seems to be crucial for the impact on the growth of 
GBM tumors after injection . 
While a marginal effect of wild-type virus is detectable after an ubiquitous intratumoral 
application via mixing of infected and uninfected cells followed by injection, solid 
GBM tumors seem not to be efficiently penetrated by adenoviruses of the serotypes 5 
and 35 after application via intratumoral injection. This supports our theory that the major 
advantage of TRAIL expressing adenoviral vectors is the rapid induction of cell death via 
apoptosis together with an advanced capability of tumor tissue penetration after 
injection.  However the tumor inhibiting effect of Ad5/35.IR-E1A/TRAIL dissipates after a 
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Although a significant oncolytic effect after intratumoral Ad5/35.IR-E1A/TRAIL injection 
can be detected for over a week. This does show that the viral vector is generally 
capable of infection, replication and transgene expression .  However the tumor 
reducing effect fades away after 3-4 complete viral replication circles and we do not 
observe a continuing effect of intratumorally build up particles.  Several mechanisms can 
be discussed that could lead to the short term effect of the oncolytic vector: 
One possibility is that a U-87 MG tumor growing  shows a different surface 
membrane expression pattern as monolayers do . We were able to rule this out 
because dissections of subcutaneously grown tumor tissue did show strong expression 
of the primary receptor CD46 [Figure 26] , demonstrating that reduced viral effect 
due to “  fading” of the viral receptor is unlikely. 
Human GBM has been found to have a multitude of resistance mechanisms that can be 
developed during gliomagenesis, and the GBM tissue itself becomes highly 
heterogeneous if growing . As previously discussed in case of the human cell line 
T98G it has been shown that a strong phosphorylation of p68 mediates resistance to 
TRAIL (157). 
Therefore resistant sub-populations that are less susceptible to TRAIL could emerge and 
subsequently be not affected by the vector. In fact several further mechanisms that can 
render a cell less sensitive to TRAIL mediated apoptosis have been shown [Figure 27].
The human inhibitor-of-apoptosis proteins (IAP) binds directly to caspases and inhibits
the enzymatic activity that executes the cell death program. IAP gene amplifications and 
protein overexpression have been found in many tumors including malignant glioma 
(143,158).
Another caspase inhibitor is the FLICE-inhibitory protein (FLIP) which blocks TRAIL-








                                                                                    5. DISCUSSION




mediated alteration of FLIP-mRNA translation leads to the FLIP splice inhibiting variant 
FLIPs. mTOR in turn is activated by the phosphatidylinositol 3-kinase (PI3K) /protein 
kinase B (PKB)/Akt. It has been shown that the Akt pathway is highly upregulated in 
70% of human gliomas examined (159,160). 
Upregulated Akt pathway and/or low levels of pro-caspase 8 in human GBM can lead to 
TRAIL resistance as  factors FLIP and PED/PEA-15 directly compete with procaspase-8 
for Fas-associated death domain (FADD) binding. Therefore low levels of procaspase-8 
and high levels of the inhibitors PED/PEA-15 and c-FLIP inhibit the formation of the 
DISC and neutralizes the extrinsic pathway.
     
  
: Low levels of procaspase-8 in combination with 
factors that compete with Fas-associated death domain (FADD) binding disrupts the apoptosis death 
inducing complex (DISC) formation while inhibition-of-apoptosis proteins (IAPs) bind to pro-caspases and 
inhibit their enzymatic activation thus stopping the cascade leading to apoptosis.   
Although these resistance mechanisms have been previously described we dismissed 
the possibility of an emerging TRAIL resistance for two reasons. Firstly TRAIL resistance 
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has been shown in case of T98G, yet the cell line is susceptible for TRAIL mediated 
induction of apoptosis [Figure 14, Figure 19] as the oncolytic transgene is expressed in 
high levels intracellular which is most likely to overcome potential cellular adverse effects 
shifting the balance towards apoptosis. Furthermore we did not see any fast developing 
resistance in case of subcutaneous tumors where virus was introduced prior to 
injection. In this case the oncolytic effect of Ad5/35.IR-E1A/TRAIL had been steady and 
long term as tumors were still significantly smaller compared to the negative control a 
month after injection [Figure 24]. Instead, this observation led us to another conclusion: 
  
Direct comparison between the long-term effect of  application of Ad5/35.IR-
E1A/TRAIL and the intratumor injection of virus sheds light on the possible effect that 
causes the lack of long-term oncolysis. In case of  application, a mix of uninfected 
an  infected cells is injected subcutaneously, causing a significant long term 
reduction of tumor growth as compared to the mock tumors [Figure 24]. This finding is 
contradicted by the approach via intratumoral application where a first significant effect 
after injection diminishes quickly [Figure 25]. The main difference in these two 
experimental approaches is the form of application of the oncolytic vector. Application of 
infected and non infected cells leads to a relatively homogeneous spread of Ad5/35.IR-
E1A/TRAIL particle producing cells through the resulting tumor. However, viral 
intratumoral injection exposes only a small section of the tumor to a large dose of virus. 
In case of the tumors formed with  transduced cells Ad5/35.IR-E1A/TRAIL
oncolysis and spreading happens on a multitude of different sites while after injection the 
main viral load is restricted to the injection site [Figure 28]. 
Hence, we hypothesize that if Ad5/35.IR-E1A/TRAIL is injected into the tumor the virus 
is generally able to transduce cells at the injection site leading to the observed oncolytic 
effect. Our examination of subcutaneously grown tumors revealed that the centers of the 
tumors are largely necrotic and do not support viral replication while virus is unlikely to 
diffuse through necrotic areas. Furthermore staining for factors as CD46 revealed 
stroma-like areas with excessive amounts of extracellular matrix proteins within the 
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composition is more likely a center of apoptotic tissue surrounded by dense, invading 
GBM cells that seem to be divided into sections by large areas of ECM [Figure 26, 
Figure 29]. We hypothesize that if Ad5/35.IR-E1A/TRAIL is injected into the tumor the 
virus is able to transduce cells at the injection site leading to the observed oncolytic 
effect. Followed by this however, virus will reach the observed sites with large amounts 
of ECM and be incapable to diffuse through these areas. This leads to an end of further 
tumor penetration and tumor tissue that had been unaffected by Ad5/35.IR-E1A/TRAIL 
infection is able to reach quickly growth rates that overcome the hampered viral 
transduction [Figure 29].
: Viral spread in the applied  tumor models. (1) Transduced cells are mixed and injected 
leading to a homogenous spread of virus producing cells within in the emerging tumor. (2) Intratumoral 
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Figure 29:  Failure of viral tumor penetration due to intratumoral extracellular matrix stroma 
structures.
5.8 Outlook 




(A) U-87 MG tumor sections stained for CD46 at 10x magnification.. Areas of dense tumor cell 
layer with abundant CD46 green arrow) are disconnected by regions of ECM/stroma protein (red arrows) .                                                                       
(B) Suggested consequence of this observation: subsiding oncolytic effect due to interrupted viral spread by 
“ECM-compartimentation”. (1) Tumor features necrotic core and compartimentation by stroma like sections 
of ECM protein with only few embedded GBM cells. (2) Ad5/35.IR-E1A/TRAIL injected into the tumor begins 
to spread and lyses infected cells around the injection site until (3) virus can not diffuse through ECM 
compartments or the necrotic core stalling further intratumoral viral activity.
In the 1990s, experiments with selectively targeted vectors for human glioma where 
performed using retroviral vectors. Limited by low titers and unstable virus particles the 
use of virus producing cells (VPCs) instead of direct viral injection into the brain had to 
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migration which limits their usefulness severely (163). Bystander and tumor transduction 
rates were considerably lower than observed in preclinical studies (162,164, 165).
Adenoviral vectors on the other hand express transgenes at high levels, can be 
produced in high titers, and infect both dividing and non-dividing cells. Studies 
comparing either retrovirus producing cells and replication deficient adenoviral vectors 
efficiency in transducing human glioma tumors found higher gene transfer efficiency and 
greater survival times with replication deficient adenoviral vectors (166,167).
However clinical trials showed that the amount of adenoviral particles, that can be 
administrated safely, is limited.  While viral vector amounts below 1012  particles showed 
no systemic toxicity, intratumoral  injection of  2×1012 viral particles resulted  in side 
effects like confusion, hypoatremia and seizures in patients (168, 169). Unfortunately
this limit of administrable vector proved to be a serious handicap and the therapeutic 
efficiency seen with replication deficient vectors showed that these restrictions were 
indeed essential as studies transitioned from pre-clinical to clinical trials. 
This did cause a resurgence of studies using of oncolytic replicating viral vectors as it 
became clear that their benefits would outweigh concerns about toxicity to normal tissue 
which had previously limited their study in humans. Although a variety of  viruses, 
namely herpes simplex virus, adenovirus, influenza virus, vaccinia virus, vesicular 
stomatitis virus, Newcastle disease virus, poliovirus, and reovirus have all been
investigated for clinical oncolytic virus therapeutics, only adenovirus and herpes simplex 
virus have entered a larger number of clinical trials (170, 171).
Among the replicating adenoviral vectors, ONYX-15 has been used in first clinical trials 
of glioma.  In this vector the E1b region was rendered unable to replicate in cells with 
normal p53 function as the inactivation of p53 is necessary for viral replication, thus 
allowing the virus to selectively replicate in cancer cells without p53 activity (171). In a 
first phase one trial the viral toxicity and MTD in resected glioma patent was examined 
and a maximum dose was not identified with up to 1×1010 pfu being well tolerated (172).
No systemic toxicity was observed even with elevated levels of anti-adenoviral 
antibodies in several patients. It has been encouraging to observe that patients who
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failed multiple previous treatments, including surgery, chemo- , and radiotherapy,
responded to oncolytic therapy with this vector. For multiple types of tumors however 
even the clinically extensively tested and optimized ONYX-015 vector type showed only 
limited effects in patients with refractory head and neck cancer (173). Furthermore it has 
been shown that once virotherapy is discontinued, patients suffered early relapses.  
Unfortunately it has to be assumed that similar bleak results will be seen in case of 
clinical trials with  ONYX- 015 and GBM as in a first phase one trial patients median 
survival was only 6.2 months from recurrence (172) .
The results of the clinical trials show that several further improvements in virotherapy are 
needed to be combined in one oncolytic vector in order to become a viable treatment 
alternative for GBM patients in the clinic: 
The virus  needs  the ability to selectively replicate and spread in the tumor mass while 
safely delivering therapeutic genes to target tissues without causing side effects or 
systemic toxicity even if the vector is applied in high doses. Ideally a therapeutic gene 
product needs to be expressed in high levels long term to generate effective, durable 
responses for the cancer patient. It has already been discussed that simply oncolytic 
capabilities of a viral vector will not be sufficient but that “armed” therapeutic viruses  
combining the lytic capability of the virus with the capacity to deliver therapeutic factors 
are necessary to effectively attack the complexity associated with human tumors (174). 
The delivery of an oncogene is in turn limited to the transduction abilities of the oncolytic 
vector.  Since widespread distribution of gene therapeutic products is essential for the 
efficacy, development of vectors which promote targeted high level transduction 
efficiency is desired. Alas, current virotherapy vectors are not efficient enough to insure 
infection of even the majority, much less all, of the tumor cells even after direct 
intratumoral injection.  In fact GBM cell transduction and GBM tumor tissue penetration 
seems to be the limiting factor of current oncoviral therapy.  
In this study we also experienced obstacles in case of tumor penetration with our 
Ad5/35.IR vector as has been reported elsewhere with other viral agents. Lack of 
intratumoral spreading can be caused by tumor stroma and has been reported in case of 
different tumor tissues (175). A GBM tumor growing  is not just a collection of cells in vivo
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but consists of necrotic areas, vascular-, and interstitial extracellular compartments. It 
seems to be extremely difficult for progeny viral vectors to spread through solid tumor as 
viral particles are not capable of bypassing intratumoral ECM/stroma structures.      
Oncolysis and viral spread is eventually stopped by these structures and instead of 
progress by broad tumor tissue transduction the infection trickles away. Therefore any 
impact on tumor tissue can only be detected short term after initial transduction.
To approach the encountered problems in glioma treatment while further improving
oncolytic therapy of human GBM, different approaches can be followed in order to 
compensate for the drawbacks reported in this study and elsewhere.
Invasive tumor penetration using carrier cells  
It has been shown that GBM transduction after injection of current virotherapy vectors 
does not insure infection of the majority of cells. While tumor cells directly at the injection 
site will most likely be transduced, the decline of this effect away from the actual site 
seems to be rather exponentially.  Therefore intratumoral injection into solid tissue 
or application into a surgery site is not the ideal form of application as the access to 
GBM cells with primary virus is very limited. 
Therefore enhanced tumor penetration by homing cells has been discussed to be 
suitable for human GBM. Human bone marrow-derived mesenchymal stem cells (MSCs) 
have been reported to home specifically into the tumor site and so do transgenic Pmel-1 
T-cells (176, 177). Transduced cells can home randomly to the tumor site followed by 
release of progeny oncolytic viral vectors. Application of homing cells without the 
necessity of direct intercranial access to the tumor is another advantage of this approach 
as, unlike direct intratumoral injection, the application frequency could be independent 
from surgical interventions.    
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First  experiments using a rodent glioma model have proven that stem cell 
application leads to a significant migratory capacity. Furthermore apoptotic cells were 
increased more than two-fold in animals treated with MSCs that had the ability to 
express the agents cytosine deaminase and IFNßagainst (178).
Improvement of tumor penetration through degradation of intratumoral ECM-
structures 
The creation of intratumoral physical barriers formed by stroma proteins seems to be 
one of the major factors causing the here and elsewhere reported dismal outcomes of 
 experiments and clinical trials in which human GBM has been treated with oncolytic 
viral vectors. Degradation of these structures might render the tumor more accessible for 
virotherapy. This hypothesis has been supported by the finding that direct administration 
of collagenase/dispase into glioma xenografts leads to an enhanced extent of infection 
of an adenoviral vector expressing a reporter gene (179). This shows that the 
degradation of tumor stroma does indeed enhance the intratumoral spread in human 
GBM and might have a significantly positive impact on GBM virotherapy.
Unfortunately direct intratumoral injection of collagenase it is not a likely option in case of 
GBM treatment of patients due to the limited access to the tumor site and problematic 
task of locating the tumor invasion sites during surgery.  However a localized expression 
of an ECM degrading factor might lead to the desired effects. Recently, relaxin (Rlx), a 
peptide hormone that has the ability to degrade stroma proteins intratumorally, has 
already been successfully utilized for this purpose  (180). Transplantation of 
mouse HSCs transduced with an Rlx- expressing lentivirus vector has been shown to 
delay tumor growth in a mouse model of breast cancer.  We predict that Rlx mediated 
degradation of tumor stroma after expression by a targeted adenoviral vector should be 
feasible for GBM. The expression should break up the intratumoral stroma structures 
without increasing the toxicity of the treatment due to localized expression, thus 
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Targeting human GBM angiogenesis 
Angiogenesis, the formation of blood vessels from pre-existing vasculature, has been 
identified as an essential mechanism in tumor growth (181). Human GBM growth and 
invasion of healthy tissue relies on this mechanism. Thus, interrupting the process of 
angiogenesis has been widely discussed as a worthwhile target for GMB therapy lately. 
Angiogenesis is mainly mediated by proangiogenic growth factors such as vascular 
endothelial growth factor (VEGF) inducing proliferation, migration and tube formation of 
endothelial cells (182). To inhibit angiogenesis anti-VEGF antibodies (anti-VEGFab) 
have been developed.  It has been already been shown in a series of clinical trials that 
anti-VEGF antibodies slow tumor growth by obstruction of tumor angiogenesis. However 
GBM tumors can adapt to anti-VEGFab application, rendering the tumor re-growth 
irresponsive to further treatment while tumor growth rate and invasion accelerates (183) 
.
However another similar important feature for human GBM angiogenesis is the 
interaction of endothelial cells with surrounding extracellular matrix (ECM) that is 
mediated by integrins. Integrins are transmembrane receptors composed of two subunits 
binding to ECM and base membrane proteins (184).  Cilengitide, a cyclic pentapeptide 
mimicking the Arg-Gly-Asp (RGD) binding site, was identified as a potent and selective 
integrin antagonist (185, 186) that has been shown to inhibit VEGF and bFGF-induced 
migration and tube formation . 
Cilengitide is capable of inhibiting proliferation and differentiation of endothelial 
progenitor cells playing an important role in neoangiogenesis in cancer (187). 
In a recent phase II clinical study Cilengitide monotherapy is well tolerated and exhibits 
modest antitumor activity among recurrent GBM patients (188). Another high-affinity 
ligand for several different integrin heterodimers is contortrostatin, a 13.5-kD 
homodimeric protein isolated from the venom of the southern copperhead snake 
(Agkistrodon contortrix contortrix). Contortrostatin has also been shown to inhibit tumor 
growth and angiogenesis while prolonging survival in a rodent glioma model. Moreover, 
contortrostatin appears to be well tolerated by the animal and lacks neurotoxic side 
effects (189).  Expression of Cilengitide or contortrostatin by a targeted oncolytic 
in vitro
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adenoviral vector may have potential as a novel synergistic therapy for malignant 
gliomas in the future.
Treatment of human GBM via immunotherapy
In the previous years there has been a significant effort for effective immunotherapy 
strategies for glioma that can be combined with common treatment strategies as more 
and more data suggested that patients with malignant gliomas feature a heavily impaired 
immune function. This is mainly due to downregulation of T-cell function by 
immunosuppressive cytokines inhibiting macrophage function (190) and production of 
proinflammatory cytokines (191) while regulatory T-cells (Tregs) play an important role in 
suppressing the immune response to the tumor (192). Thus countermeasures to re-
activate the suppressed immune system might be of great benefit for the patient and 
lead to synergistic effects with standard therapy. 
One way to reach this goal is the administration of so called “tumor vaccines” . Those 
“vaccines” consist of genetically engineered cells that express cytokines like interleukin 
(IL)-2 and IL-4 or (IFN)? in order to artificially stimulate the growth, differentiation and 
survival of antigen-selected cytotxic T-cells. While  IL-2 and (IFN)? secretion has shown  
severe toxcicity caused by brain edema, Il-4. expression induced an inflammatory 
response, leading to tumor regression (193).  Even though peripheral tumor vaccination 
can definitely initiate a systemic immune response against intracranial tumors the large 
amounts of tumor tissues or autologous tumor cell lines are required to generate gene-
modified tumor vaccines of a clinical grade may limit the feasibility of whole tumor 
vaccination strategies. 
Therefore direct delivery of cytokine-genes via cationic liposomes does appear to be the 
more promising approach.  In vivo experiments using nude mice implanted with human 
glioma cells intracranially or subcutaneously revealed that the local administration of 
cationic liposomes containing the human  gene induced apparent tumor growth 
reduction, prolonged survival and natural killer (NK) cell activation (194) . 
In addition, a similar growth-inhibitory effect was also observed in a syngeneic 
intracranial mouse glioma model treated with the liposome-mediated murine  gene. 
IFNß
IFNß
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This gene therapeutic system induced specific cytotoxic T-cell immunity against mouse 
glioma and the NK cells  (195) Long term local, intratumoral delivery of factors initiate a 
systemic immune response by a conditionally replicating adenoviral vector like 
AD5/35.IR  instead of single administration of liposomes might improve the observed 
effect. 
We wish to focus mainly on two aspects to improve human GBM treatment based on the 
findings of this study: 1) Specific targeting and oncolysis of tumor progression driving 
tumor stem cells and 2) enhanced viral spread through intratumoral secretion of a new 
optimized GMB-targeted transgene. For this further modifications to enhance 
effectiveness of oncolytic vectors will be necessary. 
Recently it has been shown that recurrent GBM can arise from small remaining sub-
populations of cancer stem cells (CSCs) which are highly resistant to radiation and 
chemotherapy, e.g. by featuring high levels of the DNA repair enzyme MGMT, which 
renders the re-growing tumor mass immune to the available standard treatments (196-
198). As it has been shown that primary viral transduction capability is of the essence, 
we believe it is also of great importance to find or create a viral vector that shows the 
best transduction capabilities of this recurrency driving source of CSCs.  Here we show 
that chimeric vectors utilizing the fiber protein of serotype 11 have a 2 fold enhanced 
transduction rate compared to Ad5/35 while elsewhere it has already been shown that 
serotype 3 has an improved viral tropism (199). We believe it could be of importance to 
create Ad5/3, Ad5/11 and Ad5/35 vectors for comparison of the CSC targeting and
expression abilities in human GBM cells in order to find the chimeric combination with 
the highest internalization efficiency of GBM tumor stem cells  and A 
modified capsid providing optimized transduction could be essential for the initial viral 
impact on an emerging tumor from CSCs since any viral spread after completion of the 
first completed replication cycle is based on this feature. 
Other strategies to overcome the limitations as described in this study could be the
improvement of the oncolytic effect. We believe that this could be achieved by either a 
in vitro in vivo.
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more potent apoptosis inducing transgene or a GBM targeted transgene that leads to 
non-viral mediated GBM cell killing post expression after initial transduction by oncolytic 
vectors. Viral expression followed by release of oncolytic peptides could enhance the 
bystander effect of the treatment by GBM cell killing in a non-viral mediated manner 
while the targeting ensures that the toxicity is not increased by undirected diffusion of the 
transgene. Intratumoral stroma structures on the other hand, which have been shown to 
have a negative impact on virus mediated GBM treatment in this study, could prove to 
be permeable and resolvable by peptides expressed after initial viral transduction.
Another approach to enhance viral tumor tissue penetration could be a change of the 
adenoviral tropism itself. While a complete viral replication circle takes 2-3 days, TRAIL 
induced apoptosis has been shown to occur hours after initial transgene expression.   
This lead us to the conclusion that the fast induction of TRAIL mediated apoptosis in 
infected cells causes generation of only few infectious units which in turn causes a
limited viral spread after initial transduction. The utilization of a transgene that is as 
reliable in GBM killing as TRAIL but effects the intracellular viral replication later would 
be desirable. Another opportunity would be the expression of a transgene that would 
unfold its oncolytic activity after an additional substrate is applied. The expression of the  
thymidine kinase of the Herpes Simplex Virus followed by application of Ganciclovir is an 
example for an extensively examined system for the treatment of a variety of cancers 
including clinical trials with glioblastoma patients in this way (200, 201). The viral 
thymidine kinase is capable of converting the non-toxic Ganciclovir by phosphorylation 
which leads to highly-toxic triphosphates that lead to cell death. Human thymidine 
kinase, in contrast, with its more narrow specificity, is unable to phosphorylate and 
activate the prodrug. In this way, only cells expressing the viral kinase are susceptible to 
the drug. A system like this would allow for “timed” cell killing using a pro-drug and 
therefore give the opportunity to optimize the best time point of infectious particle 
release. Maximized amounts of infectious particles might lead to improved viral 
intratumoral spread and furthermore enhance the long term effect of an oncolytic therapy 
in human GBM.
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We show that the capsid modification of the Ad5/35.IR-E1A/TRAIL vector leads to 
improved infection while the expression of TRAIL in the adenoviral context and 
significantly enhances the ability to induce apoptosis in GBM cells  and .
Our findings show that the commonly used wild-type serotype 5 adenovirus is inferior to 
Ad5/35 chimeric constructs. Based on these findings we conclude that Ad5/35.IR-
E1A/TRAIL is a better vector system for clinical studies with oncolytic adenovirus 
vectors. Furthermore, wild-type 5 is commonly occurring in humans leading to a immune 
response to the viral fiber proteins of potential clinical vectors, while subgroup B Ad 
vectors do not decrease in the presence of anti-Ad5 antibodies, and seroprevalences of 
most subgroup B Ads are lower than that of Ad5, indicating that clinical use with 
subgroup B Ad vectors is unlikely to be hampered by preexisting anti-Ad antibodies
Ad5/35.IR-E1A/TRAIL was able to transduce and lyse U-87 MG cells including the 
cancer stem cells sub-population. U-87 MG tumorspheres where effectively transduced 
and showed cell killing after Ad5/35.IR-E1A/TRAIL infection. As human GBM stem-like 
cells are discussed to be a major factor in recurrence of glioma due to their resistance to 
standard therapy Ad5/35.IR-E1A/TRAIL could become a useful potential therapeutically 
approach as the safety of the vector allows it to be introduced after surgery with the goal 
to eradicate stem-cell like tumor cells that do not respond to standard therapy.  
The rapid and efficient apoptosis induction in infected GBM cells and the enhanced 
intratumoral spread together with a significant growth impairment of tumors after 
injection compared to adenoviral wild-type virus indicate that the adenoviral vector 
Ad5/35.IR-E1A/TRAIL is generally a potent new approach for a potential viral gene 
therapeutic treatment of glioblastoma.
Even though we were able to show that Ad5/35.IR-E1A/TRAIL effectively spreads in 
GBM tissue after injection the effect on tumor growth on human solid GBM was only 
short term. We believe that the structure of GBM is responsible for the interruption of 
viral intratumoral penetration. Hence further improvements will be necessary to 
maximize the oncolytic effect. 
in vitro in vivo
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Despite a variety of treatment strategies including surgery, radiation therapy and 
chemotherapy, prognosis of patients with Glioblastoma multiforme (GBM) has remained 
poor. As there is need for novel and improved therapeutic approaches we tested an 
engineered chimeric adenoviral vector for the efficient treatment of GBM. The vector 
combines several aspects that enhance treatment of malignant disease, such as the 
adenovirus serotype 5 (Ad5) capsid with the adenovirus serotype 35 (Ad35) fiber protein 
which binds human CD46 instead of the underrepresented Ad5 receptor CAR. The 
vector replicates specifically in tumors due to deletion for all E1A and E1B genes 
combined with an expression cassette modification allowing for expression of the 
transgenes AdE1A and the TNF-related apoptosis-inducing ligand (TRAIL) in case of
tumor specific homologous recombination. The transgene AdE1A allows for efficient 
production of progeny virus while TRAIL has been shown to induce apoptosis in a 
variety of human cancer tissues including GBM. Initially we confirmed surface 
expression of CD46 in human GBM cell lines SF767, T98G and U-87 MG and efficient 
infection with Ad5/35.IR-E1A/TRAIL. Additionally, Ad5/35.IR-E1A/TRAIL showed 
enhanced tumor cell killing in all three human GBM cell lines relative to wild-type 
virus or Ad5/35.IR-E1A- vectors without TRAIL. TUNEL analysis of Ad5/35.IR-
E1A/TRAIL infected cells verified that the mechanism of i  cell death is apoptosis. 
Examination of Ad5/35.IR-E1A/TRAIL oncolytic abilities in an tumor model using 
human GBM xenografts in NOD/SCID mice showed significant inhibition of tumor 
growth. Also, detection of adenoviral proteins using an Ad-hexon capsid protein antibody 
showed efficient spread of the vector after intratumoral injection. Areas positive for 
adenovirus capsid proteins were also positive for TUNEL staining, confirming that the 
virus induces apoptosis in infected cells after  injection. Viral intratumoral injection 
lead to significant reduction of solid tumor growth but due to impeded intratumoral 
spread of progeny virus the effect proved to be short-lived. Thus, our study 
demonstrates that the use of Ad5/35.IR-E1A/TRAIL vectors offers a potential treatment 
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Trotz einer Vielzahl von Behandlungsstrategien wie Chirurgie, Bestrahlungs- und 
Chemotherapie ist die Prognose fuer Patienten mit Glioblastoma multiforme (GBM)  
derzeit sehr schlecht. Daher sind neue, verbesserte Behandlungsansätze dringend
notwendig. Hierzu wurde in dieser Arbeit ein neu entwickelter, chimärer adenoviraler 
Vektor für die Behandlung von GBM getested. Der Vektor kombiniert verschiedene 
Aspekte, die die Behandlungsaussichten von malignen Erkrankungen mit Hilfe von 
viraler Therapie verbessern könnten. Hierzu zählt der Austausch der Wildtyp-Serotyp 5 
(Ad5) Fiberproteine mit denen vom Serotyp 35 (Ad35). Ad35 Fiberproteine binden an 
humanen CD46 als Ligand, während Wildtyp Ad5 am Rezeptor CAR bindet. Der
Rezeptor CAR ist auf  Krebszellen meist unterrepresentiert. Zusätzlich hat der Vektor die 
Fähigkeit sich spezifisch in Tumorzellen zu replizieren. Dies geschieht durch die 
Deletion aller E1A und E1B Gene in Kombination mit dem Einsatz einer 
Expressionskassette, die nach tumorspezifischer homologer Rekombination aktiviert 
wird und die Transgene AdE1A und „TNF-related apoptosis inducing ligand“ (TRAIL) 
exprimiert. AdE1A ermöglicht effiziente intratumorale Produktion von neuen viralen 
Partikeln, während TRAIL die Fähigkeit besitzt, in Krebszellen Apoptose auszulösen. 
Zunächst haben wir die Oberflächenexpression von CD46 in den humanen GBM 
Zelllinien SF767, T98G und U-87 MG nachgewiesen, gefolgt vom Nachweis effizienter 
 Infektion der Zellen mit dem Vektor Ad5.35.IR-E1A/TRAIL. Der Vektor löste 
stärkeres Zellsterben in allen Zellinien im Vergleich zum Wildtyp oder Ad5.35.IR-E1A 
ohne TRAIL aus. Analyse mittels TUNEL-Test verifizierte, dass Apoptose-Vermittlung 
tatsächlich der Auslöser der beobachteten Abtötung der Krebszellen ist. Untersuchung 
der onkolytischen Fähigkeiten von Ad5.35.IR-E1A/TRAIL  mit Hilfe eines GBM 
Xenograft-Modells in NOD/SCID Mäusen zeigte signifikante Inhibition des 
Tumorwachstums. Detektion von adenoviralen Protein mit einem Antikörper, welcher 
gegen das Kapsidprotein gerichtet ist, zeigte effiziente virale Ausbreitung im 
Tumorgewebe. Bereiche in denen virale Kapside nachgewiesen werden konnten wurden 
ebenfalls mittels TUNEL-Färbung positiv auf Apoptose getestet. Dies legt Nahe, dass 
das Virus in der Lage ist, sich  nach Applikation im Gewebe auszubreiten und 
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soliden Tumorgewebes. Allerdings war dieser Effekt nur über einen kurzen Zeitraum zu 
beobachten. Es besteht die Möglichkeit das dies an einer behindertern intratumoralen 
Ausbreitung von neugebildeten viralen Partikeln liegt. Unsere Studie demonstriert, dass 
die Verwendung  des viralen Vektors  Ad5.35.IR-E1A/TRAIL eine neue onkolytische 
Behandlungsstrategie  für humane GBM Tumore eröffnet. Des weitern schlagen wir 
Vektor-Modifikationen vor, die nötig sind um eine potentielle Therapie effektiver zu 
gestalten.      
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